Form/Template 90702637 Rev/Ver AH  
SMART  CRT Study Protocol, 92055794, Rev/Ver  D 
April 10, 2017 , [STUDY_ID_REMOVED]   
Page 1 of 67  
  
 
 
  
Strategic MA nagement to Optimize R esponse T o Cardiac R esynchronization T herapy  
 
SMART CRT  
 
CLINICAL INVESTIGATION PLAN  
 
Reference Number C2067 
Sponsored By  
 
[CONTACT_5756], Rhythm Management (RM)  
[ADDRESS_418625]. Paul, MN [ZIP_CODE] 
 
 
Guidant Europe NV,  
A [LOCATION_011] Scientific Company 
Clinical Department Rhythm Management  
Green Square  
Lambroekstraat 5D  
1831 Diegem, 
Belgium  
 
 
 
This protocol contains confidential information  for use by [CONTACT_113627]. The protocol should be 
held confidential and maintained in a secure location. 
Do not copy or distribute without written permission from [LOCATION_011] Scientific Corporation.  
         
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                     SMART  CRT Study Protocol, 92055794, Rev/Ver  D  
                                                                                                                       Page [ADDRESS_418626]  (US)  Allison Anderson  
Clinical Trial Manager  
[ADDRESS_418627] North  
Arden Hills, MN  [ZIP_CODE] 
 
Cell: 919 -345-6001 
E-mail: [EMAIL_6565]  
Technical Service: 1.800.CARDIAC (227.3422)  
Clinical Contact 
(Europe ) Ursula Appl  
Senior Clinical Trial Manager  
[LOCATION_011] Scientific , Guidant Europe SA/NV  
Green Square, Lambroekstraat 5D  
1831 Diegem  
Belgium  
Tel: +32 -2-41-67-213 
Cell: +32 -477-31-92-18 
E-mail: [EMAIL_6566]  
Technical  Services (International): +[ADDRESS_418628]  
MSC 592 Charleston, SC [ZIP_CODE]- 5290 
[LOCATION_002]  
Vendors/Labs  A list of vendors involved in the trial is maintained by [CONTACT_456].  
 
 
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                     SMART  CRT Study Protocol, 92055794, Rev/Ver  D  
                                                                                                                       Page 3 of 67  
  Original Release: Dec 21, 2016  
Current Version: April 10, 2017  
 Revision History  
 Release Date  Template 
number and 
version  Section  Change  Reason for Change 
A 21 Dec 2016  90702637  
Rev./Ver. AH  N/A Original Release  N/A 
B 25 Jan 2017  90702637  
Rev./Ver. AH  9.3 Exclusion 
criteria  Revised exclusion 
criteria to match the synopsis for 
pregnancy criterium Correction: Was updated in the synopsis, but not in 
the body of the protocol  
C 28 Mar 2017  90702637  
Rev./Ver. AH  Current 
Version  Current Version was not updated to match 
Rev B release date Correction: Updated 
Current Version to March 28, 2017  
11.4; [IP_ADDRESS]  “Should” changed to “must”  Correction: Criteria is required for the study.  
11.4.2;  Updated: “Echocardiography 
will be used” Correction: grammatical 
error 
11.6.2  Corrected format : 
“directed to the patient to address 
how well”  Correction: grammatical 
error 
   11.5.1; 
[IP_ADDRESS]; 
11.6.1  Instructions for 
SmartDelay and 
VectorGuide 
printouts removed  Updated programmer 
software  
   11.6 Device testing not 
required to be completed prior to 
other assessments.  Correction: Requirement removed.  
D 10 Apr 2017  90702637  
Rev./Ver. AH  N/A Removal of redlines 
in version C.  New version required in order to remove redlines 
existing in previous 
document. No content change from version C.  
  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 4 of 67  
 
  2. Protocol Synopsis  
Strategic MAnagement  to Optimize Response To  Cardiac Resynchronization Therapy  
SMART CRT  
Study 
Objective(s) The primary objective is to show the benefit of  SmartDelay ™ in patients 
with a prolo nged RV- LV interval.  
Planned Indication(s) for Use  All implanted devices will be used within the current labeled indications 
for use. Cardiac Resynchronization Therapy Defibrillators ( CRT -D) are 
intended to provide cardiac resynchronization therapy and provide anti -
tachycardia pacing and defibrillation therapy . 
Device Description  All commercially approved [LOCATION_011] Scientific X4 quadripolar CRT -D 
devices and future generations of BSC X4 CRT -Ds approved by [CONTACT_338635] a  [LOCATION_011] Scientific ACUITY™ X4 quadripolar LV lead. CRT -D 
devices must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV)  and left v entricular (LV) only pacing.  
A list of approved ACUITY X4 LV leads and CRT -D models is available 
upon request.  
Study Design SMART  CRT is a prospective, double -blind, multicenter, international, 
randomized controlled  trial. 
Planned Number of Subjects  An estimated [ADDRESS_418629] 370 subjects to complete the Six Month Follow -Up. 
The study progress will be monitored, and if necessary, the number of 
patients enrolled may be increased to ensure that an adequate numb er of 
patients complete the Six Month Follow -Up.  
Planned Number of Investigational Sites / Countries  The study will be conducted at up to 100 sites globally.  
Primary Endpoint  The primary endpoint is comparing cardiac resynchronization therapy 
(CRT ) response rates between AV Delay  programming schemes  define d 
by [CONTACT_338636] a Fixed AV Delay  of 120ms . CRT response is defined 
by a decrease in Lef t Ventricular End Systolic Volu me (LVESV) ≥  15% 
at 6 months  compared to pre -implant baseline .  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 5 of 67 
 
  Strategic MAnagement  to Optimize Response To  Cardiac Resynchronization Therapy  
SMART CRT  
Additional 
Analyses Additional analyses include:  
• Clinical Composite Endpoint 
• All-cause mortality  
• Heart failure events  
• NYHA Class  
• Quality of Life (patient Global Assessment instru ment) 
• Six-minute walk  distance 
• Kansas City Cardiomyopathy Questionnaire 
• Left-ventricular ejection fraction (LVEF)  
Method of Assigning Patients to Treatment  For all subjects  enrolled and implanted with a BSC X4 CRT -D system , 
the RV- LV delay will be measured at the P ost-Implant A ssessment .  
For those subjects identified with an RV-LV delay ≥70ms, 1:1 
randomization will occur in the electronic data capture (EDC) system. Subjects will be randomized to have an AV Delay  determined by 
[CONTACT_338637] a Fixed AV Delay  of 120ms.  
Those s ubjects identified with an RV -LV < 70ms will be exited from the 
study after [ADDRESS_418630] to assess for any reportable safety events.  
Follow- up 
Schedule  Study procedures or clinic visits will occur at the following time periods:  
• Enrollment V isit (<30 days prior to implant procedure)  
• Pre-Implant V isit (<30 days prior to implant procedure)  
• Post-Implant A ssessment ([ADDRESS_418631] -implant) and 
Randomization, if applicable  
• Six Month Follow- Up Visit  (180 to 210  days after 
Randomization) 
 
Study Duration  The trial duration is estimated to be approximately 2.[ADDRESS_418632] patient follow -up. 

C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 6 of 67  
 
  Strategic MAnagement  to Optimize Response To  Cardiac Resynchronization Therapy  
SMART CRT  
Key Inclusion 
Criteria  • Subject must be indicated to receive a de novo quadripolar [LOCATION_011] 
Scientific Cardiac Resynchr onization Therapy Defibrillator ( CRT -
D) in conjunction with an ACUITY X4 LV lead. This  includes 
subjects who are indicated to receive an upgrade to a BSC X4 CRT -D from a p reviously implanted device.   
• In order to achieve a homogenous population for the study, qualifying subjects are those with heart failure who meet BSC US 
indications for use defined as those subjects who receive stable optimal pharmacologic therapy (OPT) for heart failure and who meet any one of the following classifications:  
o Moderate to severe heart failure (NYHA Class III -IV) with 
EF ≤ 35% and QRS duration ≥ 120 ms  
o Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA  Class II) ischemic or 
nonischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure  
• Subject is age 18 or above, or of legal age to give informed 
consent specific to each country and national laws  
• Subject is willing and capable of providi ng informed consent  
• 
Subject is willing and capable of complying with visits  and 
procedures  as defined by [CONTACT_338638]  • Subject s with documented permanent complete AV block  
• Subject s with permanent or chronic atrial fibrillation (AF) or in 
AF at the time of enrollment  
• Subjects who have previously received cardiac resynchronization 
therapy with pacing in the left ventricle  
• Subject s on the active heart transplant list or who has or is to 
receive ventricular assist device (VAD)  
• Life expectancy shorter than 12 months due to any medical condition (e.g., cancer, uremia, liver failure, etc…)  
• Subject with a known or suspected sensitivity to dexamethasone 
acetate (DXA)  
• Subject is enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from [LOCATION_011] Scientific  
• Women of childbearing potential who are or plan to be come  
pregnant  during the course of the trial   
• Subjects currently requiring dialysis  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 7 of 67  
 
  Strategic MAnagement  to Optimize Response To  Cardiac Resynchronization Therapy  
SMART CRT  
Statistical Methods  
Primary 
Statistical Hypothesis  The following set of hypotheses will be used to evaluate the Primary 
Endpoint:  
 
Ho: p (SmartDelay)  ≤ p (Fixed)  
H1: p (SmartDelay)  > p (Fixed)  
 
Where p represents the proportion of CRT responders.  Response is 
defined as a >15% decrease LVESV ([LVESV 6M – LVESV BL]/ LVESV BL 
< - 15%).  
Statistical Test 
Method  A chi-square test will compare the proportion of responders between the 
groups.  
Sample Size Parameters  Approximately  726 subjects are required in order to achieve 370 subjects 
to complete the Six Month Follow -Up. 
Sample size was calculated using the followi ng assumptions:  
• Effect size = 14 .25% difference (based on ability to detect at least 
75% of the 19% difference observed in SMART AV)  
• Randomization allocation = 1:1  
• Subject s contributing to analysis = 370 ( 51%) of enrolled subjects  
o 436 ( 60%) with RV- LV ≥ 70 ms  
o 370 ( 85% of randomized subject s) with complete datasets 
at [ADDRESS_418633] s with RV- LV ≥ 70 ms  
Our sample size parameters for patient enrollment were estimated based 
on experience from prior studies. These parameters will be re- evaluated 
while the study is in progress, and if necessary, adjustments may be 
made.  
  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 8 of 67 
 
    
3. Table of Contents  
1. T ITLE PAGE  ........................................................................................................................ 1 
2. PROTOCOL SYNOPSIS  .......................................................................................................... 4  
3. TABLE OF CONTENTS  .......................................................................................................... 8  
3.1. Table of Figures  ...................................................................................................... 11  
3.2. Table of Tables ....................................................................................................... 12  
4. INTRODUCTION  ................................................................................................................. 13  
5. DEVICE DESCRIPTION  ....................................................................................................... 15  
5.1. Medical Equipment Description  ........................................................................... 15  
 [LOCATION_011] Scientific’s ACUITY X4 Quadripolar LV Lead and Accessories  [ADDRESS_418634] Status and Classification  .......................................................................... 22  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page [ADDRESS_418635] ........................................................................................ 32  
 Quality of Life Global Assessment  ............................................................ 32  
11.7.  Additional Follow -Up Visits  .................................................................................. 33  
11.8.  Device Programming Outside of the Investigational Plan  ................................. 34  
11.9.  Study Completion  ................................................................................................... 34  
11.10.  Source Documents  ................................................................................... 35  
12. STATISTICAL CONSIDERATIONS  ....................................................................................... 35  
12.1.  Primary Endpoint  .................................................................................................. 35  
 Hypotheses ................................................................................................. 35  
 Sample Size  ............................................................................................... 35  
 Statistical Methods  ..................................................................................... 36  
12.2.  General Statistical Methods .................................................................................. 36  
 Analysis Sets .............................................................................................. 36  
 Control of Systematic Error/Bias  ............................................................... 36  
 Number of Subjects per Investigative Site  ................................................ 37  
12.3.  Additional Data Analyses  ...................................................................................... 37  
 Other Endpoints/Measurements  ................................................................. 37  
 Tertiary/Exploratory Analyses  ................................................................... 37  
 Primary Endpoint Sensitivity Analyses  ..................................................... 37  
 Interim Analyses  ........................................................................................ 38  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page [ADDRESS_418636]/ Ethics Committee  ................................................... 43  
16.4.  Sponsor Responsibilities  ........................................................................................ 43  
 Role of [LOCATION_011] Scientific Representatives  ................................................ 43  
16.5.  Insurance ................................................................................................................. 44  
17. MONITORING  ..................................................................................................................... 45  
18. POTENTIAL RISKS AND BENEFITS  .................................................................................... 45  
18.1.  Anticipated Adverse Events  .................................................................................. 45  
18.2.  Anticipated Adverse Device Effects ...................................................................... 46  
18.3.  Risks Associated with Participation in the Clinical Study  ................................. 47  
18.4.  Risk Minimization Actions  .................................................................................... 47  
18.5.  Anticipated Benefits  ............................................................................................... 47  
18.6.  Risk to Benefit Rationale  ....................................................................................... 47  
19. SAFETY REPORTING  .......................................................................................................... 47  
19.1.  Reportable Events by [CONTACT_142186]  .......................... 47  
19.2.  Definitions and Classification  ............................................................................... 48  
19.3.  Relationship to Study Device(s)  ............................................................................ 50  
19.4.  Investigator Reporting Requirements .................................................................. 52  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 11 of 67  
 
  19.5.  [LOCATION_011] Scientific Device Deficiencies .................................................................... 53 
19.6.  Reporting to Regulatory Authorities / IRBs / ECs / Investigators  .................... [ADDRESS_418637] Death Reporting  ....................................................................................... 54 
20. INFORMED CONSENT  ......................................................................................................... 55 
21. COMMITTEES  .................................................................................................................... 56 
21.1.  Safety M onitoring Process  ..................................................................................... 56 
21.2.  Steering Committee  ................................................................................................ 56 
21.3.  Clinical Events Committee  .................................................................................... 56 
22. SUSPENSION OR TERMINATION  ......................................................................................... 57 
22.1  Premature Termination of the Study  ................................................................... 57 
22.1.1  Criteria for Premature Termination of the Study  ....................................... 57 
22.2  Termination of Study Participation by [CONTACT_71636]/ EC Approval  .................................................................................................. [ADDRESS_418638] Follow -up ................................. 57 
22.4  Criteria for Suspending/Terminating a Study Site  ............................................. [ADDRESS_418639]  ............................................................................................ 64 
27.3.  Kansas City Cardiomyopathy Questionnaire (KCCQ)  ...................................... 66 
27.4.  SmartDelay Step -by-Step Guidance  ..................................................................... 66 
 
3.1. Table of Figures  
Figure 5- 1: ACUITY X4 Leads and Electrode Placement  ..................................................... 16 
Figure 5- 2: SmartDelay Example  ........................................................................................... 17 
Figure 5- 3: LV VectorGuide Example  ................................................................................... 17 
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 12 of 67  
 
  Figure 8- 1: SMART CRT Study Design  ................................................................................ 18 
Figure 11- 1: Post -Implant Assessment  ................................................................................... 29 
Figure 11- 2: Quality of Life Global Assessment  .................................................................... 32 
 
3.2. Table of Tables  
Table 8 -1: Treatment Arms  ..................................................................................................... 19 
Table 9 -1: Inclusion Criteria  ................................................................................................... 20 
Table 9 -2: Exclusion Criteria  .................................................................................................. 21 
Table 11- 1: Data Collection Schedule  .................................................................................... 24 
Table 11- 2: Source Documentation Requirements – Enrollment Visit  .................................. 25 
Table 11- 3: NYHA Classifications  ......................................................................................... 26 
Table 11- 4: Source Documentation Requirements – Pre -Implant Assessment  ...................... 27 
Table 11- 5: Source Document Requirements – Post -Implant Assessment and Randomization
 ............................................................................................................................. 31 
Table 11- 6: Source Document Requirements – Six Month Visit  ........................................... 33 
Table 11- 7: Additional Follow -Up Visit Data Collection  ...................................................... 34 
Table 18- 1-1: Potential Adverse Events for Implantation of a Pulse Generator and/ or Lead 
System Implants  ................................................................................................... 45 
Table 19- 1: Safety Term Definitions  ...................................................................................... 48 
Table 19- 2: Criteria for Assessing Relationship of Study Device or Procedure to Adverse 
Event  .................................................................................................................... 51 
Table 19- 3: Investigator Reporting Requirements  .................................................................. 52 
Table 26- 1: Study Abbreviation  .............................................................................................. 61 
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 13 of 67  
 
   
4. Introduction  
Heart failure may be exacerbated by [CONTACT_338639].  
This delay in conduction, evidenced by [CONTACT_338640], often results in an 
inefficient asynchronous contraction pattern. Cardiac resynchronization therapy (CRT) is the application of electrical stimuli to both ventricles with an implanted device.   
Cardiac r esynchronization therapy, when combined with defibrillation (CRT -D) was first 
demonstrated to be safe and effective in the CONTAK CD study
1. This study showed that 
defibrillator patients with NYHA Class III- IV heart failure, reduced ejection fraction, and 
wide QRS who randomized to CRT -D On had significantly improved exercise performance, 
reduction in symptoms, increased quality of life, and improved cardiac structure and function 
when compared to patients randomized to CRT -D Off.   
The COMPANION study was a subsequent study of patients NYHA Class III -IV heart 
failure, reduced ejection fraction, and wide QRS. Unlike the prior CONTAK CD study, 
patients in COMPANION were not indicated for a defibrillator. Patients in this study were 
randomized on a 2:2:1 basis to CRT -D, CRT -P (CRT without a defibrillator), or optimal 
pharmacological therapy. COMPANION not only confirmed the re sults from the CONTAK 
CD study, but demonstrated additional benefits of CRT that included significant reduction in 
all-cause mortality, both alone and in combination with hospi[INVESTIGATOR_338618] -causes, 
cardiovascular causes, or heart failure2.    
The study of CRT -D was extended in the MADIT CRT trial to defibrillator patients with 
NYHA Class I -II, reduced ejection fraction, and wide QRS. Like the COMPANION study 
before it, M ADIT CRT showed that CRT -D was associated with significant reduction in all-
cause mortality in combination with heart failure hospi[INVESTIGATOR_338619] a defibrillator alone3. MADIT CRT also demons trated significant reduction in left 
ventricular volumes and improvement in left ventricular ejection fraction.  
The benefits of CRT -D are not conferred on every patient implanted with a device, however.  
Patients who fail to show improvement are typi[INVESTIGATOR_338620] “non -responders”. There is 
no universally accepted metric for defining response. Commonly used outcome measures in clinical practice include symptomatic relief, quality of life, or exercise tolerance.  Improvements in echocardiographic param eters (left ventricular dimensions/volumes and left 
ventricular ejection fraction) may also be used. Large scale clinical trials tend to use composite endpoints, of which the Clinical Composite Endpoint (CCE)  is the most widely used
4. This endpoint combines four metrics: all -cause mortality, heart failure hospi[INVESTIGATOR_059], 
NYHA Class, and quality of life as measured with the patient global assessment instrument. When clinical metrics are used, the typi[INVESTIGATOR_15385] -response rate cited is one -third of patients are 
non-responders. When echo- based measures are used, the non -response rate is somewhat 
higher.  
The potential reasons for non- response are varied and include
5: 
• Poor lead location  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 14 of 67  
 
  • Lack of baseline electrical dyssynchrony 
• Improper programming  
• Irreversibly adva nced heart failure  
• Myocardial scar  
 
Device- based features have been introduced that modify how CRT is delivered.  These 
include:  
• Interventricular timing (V -V timing)   
• AV Delay  
• Multi -site pacing  
• LV-only CRT  
To date, the randomized clinical studies conducted have shown equivalence with 
conventional CRT delivery without demonstrating superiority although subsequent subgroup analyses suggest that some patients may be helped.  
V-V Timing : The InSync III Marquis Study
6 using the CCE, D ECREASE HF Study7 using a 
composite of peak VO2 and L VESD, and RHYTHM ICD V- V Optimization Study8 using 
peak VO2 all demonstrated the safety of this feature and non- inferiority to conventional 
sequential biventricular pacing, but none showed superiority.  
LV Only CRT : The DECREASE HF Study7 using a composite of peak VO2 and LVESD and 
the B -LEFT HF Study9 using the CCE demonstrated safety of LV pacing but neither showed 
that LV Only CRT was superior to conventional biventricular CRT. The AdaptivCRT study, using the CCE, evaluated an algorithm that provided either LV or biventricular pacing depending on AV conduction while  also periodically adjusting AV delay and V -V timing.  
This algorithm was found to be non -inferior to echocardiographic -guided optimization
10.  
AV Delay: Randomized studies to determine the effectiveness of optimizing AV delay have 
been based on algorithms that use measurements of intrinsic conduction to establish an AV 
delay. These studies include FREEDOM11 (which also included  a V-V timing optimization 
algorithm) and used the CCE and SMART -AV12 which used LVESV, which showed these 
methods were non- inferior to empi[INVESTIGATOR_338621]. The RESPOND -CRT study, which 
evaluated a CRT system that employed a hemodynamic sensor to optimize both AV and VV timing, used a modified version of the CCE. This study as well found that the sensor was 
non-inferior to echocardiographic optimization
13.  
Multi -site Pacing: To date, results from only one randomized clinical trial on multi- site 
pacing has been presented. The MPP Trial, using a modified version of the CCE, evaluated a 
CRT -D system that pace d the left ventricle from two distinct sites using a quadripolar lead14. 
The study had a 3 month run- in phase that identified non -responders who were then 
randomized to MPP or conventional CRT. MPP was found to be non- inferior to conventional 
CRT in converting non- responders to responders. 
Given that no major randomized trial has prospectively shown superiority to conventional methods of delivering CRT, emphasis has shifted to tailoring CRT to a given patient’s intrinsic electrophysiologic characteristics. Left ventricular electrical delay (LVED), which is a measure of the difference in time between an intrinsic ventricular depolarization being 
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page [ADDRESS_418640] from the surface 
lead II ECG as one timing reference and appearance of unpaced ventricular depolarization on the left ventricular lead as the othe r. In this retrospective analysis that used reduction in 
LVESV as its primary endpoint, prolonged values of QLV were significantly associated with progressively greater degrees of reverse remodeling. The role of interventricular delay was examined again by  [CONTACT_338641]
16, but this time using data from the implanted CRT -D device 
instead of external hardware. For this analysis, interventricular delay was measured as the elasped time between unpaced ventricular depola rization detected on the right ventricular 
lead and the left ventricular lead (RV -LV). The same relationship was observed with RV- LV 
based subgroups that was previously observed with QLV, namely, that progressively larger values of RV- LV were significantly  associated with greater reductions in left ventricular 
volumes and improvement in left ventricular ejection fraction and quality of life.   
This retrospective observation that SmartDelay was more effective with prolonged RV -LV is 
the basis for the SMART CR T study. The objective of the SMART CRT study is to confirm 
this finding prospectively. 
5. Device Description 
5.1. Medical Equipment Description  
Commercially approved quadripolar [LOCATION_011] Scientific (BSC) Cardiac Resynchronization 
Therapy Defibrillator (CRT -D) devices and future generations of BSC X4  CRT -D devices 
approved by [CONTACT_338642]. All devices utilized in the study will include SmartDelay™  (5.1.2) and must be capable of providing 
SmartDelay recommendations for both biventricular pacing  (BiV)  and Left Ventricular (LV ) 
only pacing . Additionally, all CRT- D devices will utilize  LV VectorGuide™ ( 5.1.3 ). A list of 
approved CRT- D models is available upon request.  
A commercially approved BSC Right Atrial (RA) lead and Right Ventricular (RV) lead are 
recommended to be included in this study, but any commercially available RA lead and RV lead from any manufacturer are  eligible. [LOCATION_011] Scientific’s ACUITY™ X4 IS4 heart fa ilure 
lead family for the LV  lead ( 5.1.1) will be required. 
 [LOCATION_011] Scientific’s ACUITY X4 Quadripolar LV Lead and 
Accessories  
[LOCATION_011] Scientific’s ACUITY™ X4 IS4 heart failure lead family for the Left Ventricle (LV) leads are required in this study   (Figure 5-1: ACUITY X4 Leads and Electrode Placement ). 
The ACUITY X4 leads are  intended for chronic left ventricular pacing and sensing. A variety 
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 16 of 67  
 
  of pace/sense configurations are possible with the four distal electrodes that can function as 
cathodes (all four electrodes) or anodes (all except E1, the most distal electrode) when used with a compatible pulse generator. ACUITY X4 leads are available in three tip configuration designs (straight tip, short tip spi[INVESTIGATOR_23585], long tip spi[INVESTIGATOR_23585])—intended to provide choices for a variety of patient anatomies. Available ACUITY X4 LV leads include: 4671, 4672, 4674, 
4675, 4677, 4678. 
 
Figure 5-1: ACUITY X4 Leads and Electrode Placement  
Note: Nomenclature of electrodes on the lead is E1, E2, E3, E4. The corresponding nomenclature on the BSC PRM is as foll ows:  
E1: LV Tip 1  
E2: LV Ring 2 E3: LV Ring 3  
E4: LV Ring 4 
  
 SmartDelay  
The SmartDelay optimization feature quickly (<2.5 minutes) provides recommended settings for programming paced and sensed AV Delays and pacing chamber (LV vs. BiV) based on the measurement of intrinsic AV intervals. The objective of the feature is to recommend AV Delays that provide optimally timed CRT, which maximizes contractile function.  
The SmartDelay optimization test evaluates right and left ventricular response to both atrial sensed and paced events to determine suggested settings for the following: Paced AV Delay (PAV), Sensed AV Delay (SAV), pacing chamber(s).  

C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 17 of 67  
 
   
Figure 5-2: Sm artDelay Example 
 
 LV VectorGuid e 
LV VectorGuide allows the clinician to evaluate multiple quadripolar LV pacing vectors  
quickly to identify the desired configuration. The following tests can be assessed in each 
pacing configuration from the LV VectorGuide screen:  
• RV sense (RVs) to LV sense (LVs) timing  (RV-LV Delay ), the delay between 
detection of an intrinsic R -waves between the RV and LV EGMs   
• LV lead impedance  
• LV pace threshold  
• Phrenic Nerve Stimulation (PNS) 
 
Figure 5-3: LV VectorGuide Example  

C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 18 of 67  
 
  6. Study Objectives  
The primary objective is to  show the benefit of SmartDelay  in patients with a prolonged RV-
LV interval.   
7. Study Endpoints  
The primary endpoint is comparing cardiac resynchronization therapy (CRT) response rates 
between AV Delay  programming schemes defined by [CONTACT_338636] a Fixed AV Delay  of 
120ms.CRT response is defined by a decrease in LVESV of ≥ 15% at [ADDRESS_418641] 370 subjects to complete the Six 
Month Follow- Up. The study progress will be monitored, and if necessary, the number of 
patients enrolled may be increased to ensure that an adequate number of patients complete the Six Month Follow-Up. The final sample size will be determined via an interim sample size re- assessment, as described in Section  
12.1.2.  
 
Figure 8-1: SMART CRT Study Design  
 
8.2. Treatment Assignment  
The RV- LV interval will be measured at the P ost-Implant A ssessment f or all subjects 
enrolled and implanted with a BSC X4 CRT -D system . For those subjects identified with an 

C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 19 of 67  
 
  RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. 
Subjects will be randomized to have either an AV Delay  and pacing chamber determined by 
[CONTACT_338643] a Fixed AV Delay  of 120ms with BiV pacing . Randomization schemes can be 
obtained by [CONTACT_338644] (EDC) and registering the 
subject. 
Study participation ends prior to randomization assignment for subject s with a n RV- LV < 
70ms (as shown in  Figure 8-1: SMART CRT  Study Design). Subjects with an RV -LV < 
70ms will be exited from the study after [ADDRESS_418642] to assess for any reportable safety 
events.  
 Treatment Arms  
There will be two treatment arms of the trial:  
Table 8-1: Treatment Arms  
ARM 1= AV Delay  and pacing chamber 
determined by [CONTACT_338645] 2 = Fixed AV Delay  at 120ms  with 
BiV pacing  
8.3. Justification for the Study Design  
NYHA Class I -II patients are now eligible for CRT following the MADIT CRT study3, and 
there are no prior data for these patients using the SmartDelay  feature.  Furthermore, in the 
intervening seven years since the SMART AV trial results were first published , there have 
been changes in technology. Q uadripolar leads are available and in use today rather than the 
unipolar/bip olar leads previously available. P otential changes in implant technique 
(optimizing lead position for position rather than electrical performance) as well as potential changes in the practice of medicine when treating heart failure patients.  Accordingly, a randomized controlled  trial was chosen.  This study design helps assure that two comparable 
patient populations are obtained while mitigating bias such that any observe d changes are 
due to the use of SmartDelay  alone. 
The parameters for the study design were taken from the predicate SMART AV study. The SMART AV study was designed to detect a decrease in LVESV of at least [ADDRESS_418643] 15%. The modification in the response definition for SMART CRT was made to represent a more appropriate clinical definition of CRT response.  Increasing values of RV -LV were associated 
with an increased effect size. The cutoff value of [ADDRESS_418644] 75% of the effect size to conserve a clinically meaningful proportion of the effect observed in SMART AV. 
 
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418645] Selection  
9.1. Study Population and Eligibility  
Subjects included in the SMART CRT Study should be selected from the investigator’s 
general patient population of patients who are indicated for CRT -D implantation per BSC 
labeled indication provided in Section 9.2. Investigators are responsible for screening all potential subje cts and selecting those who meet the eligibility criteria for the study as 
described in Sections 9.2  and Section 9.3 below. 
9.2. Inclusion Criteria  
Subjects who meet all of the following criteria (see Table 9- 1) may be given consideration 
for inclusion in this clinical investigation, provided no exclusion criterion (see  Table 9 -2) is 
met.  
Table 9- 1: Inclusion Criteria  
Clinical Inclusion Criteria  • Subject must be indicated to receive a de novo quadripolar [LOCATION_011] 
Scientific Cardiac Resynchronization Therapy Defibrilla tor (CRT -D) 
in conjunction with an ACUITY X4 LV lead. This  includes subjects 
who are indicated to receive an upgrade to a  BSC X4 CRT -D device 
from a previously implanted device.   
• In order to achieve a homogenous population for the study, qualifying 
subjects are those with heart failure who meet BSC US indications for 
use defined as those subjects who receive stable optimal pharmacologic therapy (OPT) for heart failure and who meet any one of the following classifications:  
o Moderate to sever e heart failure (NYHA Class III -IV) with EF 
≤ 35% and QRS duration ≥ 120 ms  
o Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or nonischemic heart failure or asymptomatic (NYHA Class I) ischemic heart f ailure  
• Subject is age 18 years old or above, or of legal age to give informed 
consent specific to each country and national laws  
• Subject is willing and capable of providing informed consent  
• 
Subject is willing and capable of complying with visits and procedures 
as defined by [CONTACT_3181]  
 
9.3. Exclusion Criteria  
Subjects who meet any one of the following criteria (Table 9 -2) will be excluded from this 
clinical study.  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 21 of 67  
 
  Table 9- 2: Exclusion Criteria  
Clinical 
Exclusion Criteria  • Subjects with documented permanent complete AV block  
• Subject s with permanent or chronic atrial fibrillation (AF) or in AF at 
the time of enrollment  
• Subjects who have previously received cardiac resynchronization therapy with pacing in the left ventricle  
• Subjects on the active heart transplant list or who has or is to receive 
ventricular assist device (VAD) 
• Life expectancy shorter than 12 months due to any medical condition 
(e.g., cancer, uremia, liver failure, et c…) 
• Subject with  a known or suspected sensitivity to dexamethasone 
acetate (DXA)  
• Subject is enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, without the wri tten approval from 
[LOCATION_011] Scientific  
• Women of childbearing potential who are or plan to become pregnant 
during the course of the trial  
• Subjects currently requiring dialysis  
10. Subject Accountability  
10.1. Point of Enrollment  
Subjects who meet the eligibility cri teria and are interested in participation will be provided 
with a n informed consent approved by [CONTACT_16018]’s Institutional Review Board (IRB) / Ethics 
Committee (EC).  
All subjects who complete the informed consent process, sign and date the informed consent 
form are considered enrolled in the SMART CRT  study. No study related procedures can 
take place until the ICF is signed. Screening tests that are part of Standard of Care (SOC) can be used to determine pre -eligibility. Subjects enrolled in this investigation must be followed 
per this investigational protocol.  
10.2. Withdrawal  
All subjects enrolled in the clinical study (including those withdrawn from the clinical study 
or lost to follow -up) shall be accounted for and documented. If a subject withdraws from the 
clinical investigation, the reason(s) shall be reported.  
 Reasons f or withdrawal include, but are not limited to:  
o Subject found not to meet eligibility criteria  
o Subject choice to withdraw consent  
o BSC X4 CRT -D system was not able to be implanted  
o Pre-implant echocardiography testing not completed prior to implant  
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418646];  
 Three documented attempts to contact [CONTACT_423], including one certified 
letter, are required to declare a subject lost to follow up. 
 
If a subject withdraws from the clinical investigation, the reason(s) shall be reported on the 
End of Study electronic case report form (eCRF) in the EDC system. Data up to the point of withdrawal will be collected. All open adverse events should be closed or documented as 
chronic.  Normal manufacturer vigilance monitoring of device performance will take place 
after a subject is withdrawn.  
10.3. Subject Status and Classification  
All subjects who complete the informed consent process, sign and date the ICF are 
considered enrolled. Subject status will be classified as below after enrollment:  
Intent :  A subject who has been enrolled, but does not have anesthesia administered in 
preparation for a BSC CRT -D system implant procedure. The original Informed Consent 
form and screening documentation for intent patients should be maintained in the Center’s 
files and an End of Study form completed. Patients shall be withd rawn from the study and 
followed as per standard of care. No further follow -up is required.  
 
Partial Attempt: A subject who has been enrolled and has had anaesthesia administered in 
preparation for a BSC CRT -D system implant procedure, but does not undergo an 
implant/main study procedure.  The patient shall be contact[CONTACT_250076] [ADDRESS_418647].  
Attempt: A subject who has been enrolled, had anaesthesia administered in preparation for a BSC X4 CRT -D system implant procedure, undergoes a BSC CRT -D system implant 
procedure, but is not successfully implanted with the study system  (RA lead, RV lead, 
ACUITY X4 LV lead, and BSC X4 CRT -D). The patient shall be contact[CONTACT_250076] [ADDRESS_418648].  
Implant: A subject who has been enrolled, had anesthesia administered in preparation for a 
BSC CRT -D system implant procedure, undergoes a BSC X4 CRT -D system implant 
procedure and is successfully implanted with the study system (RA lead, RV lead, ACUITY X4 LV lead, and BSC X4 CRT -D).  
 
C2067               Form/Template 90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 23 of 67  
 
  10.4. Enrollment Control s 
Each center may enroll up to a maximum of 72 subjects , no more than 10% of [ADDRESS_418649] obtain prior written approval 
from the sponsor or sponsor’s delegated representative.  
Sites will be notified when the enrollment goal is close to being reached and once enrollment 
is complete.   
 
11. Study Methods  
11.1. Data Collection  
Data will be collected from each subject at the following visits: E nrollment  Visit, P re-
Implant  Assessment , Post-Implant  Assessment and Randomization , and Six Month Follow -
Up. Additional follow -up visits must be collected if they are associated with a reportable 
adverse event, a suspected device deficiency, or a specified device programming change. 
Routinely scheduled office visits, for purposes other than the aforementioned e vents, do not 
require additional visit forms to be completed . Subjects classified as “partial attempt ” and 
“attempt” will be contact[INVESTIGATOR_530], either in person or by [CONTACT_756], at least 30 days after the 
implant procedure in order to capture any reportable advers e events prior to withdrawal from 
the study.
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                            S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 24 of 67  
  Table 11- 1: Data Collection Schedule  
 
Procedure/Assessment  Enrollment Visit  
(< 30 days prior 
to implant)  Pre-Implant 
Assessment  
(< 30 days prior to 
implant)  Post -Implant 
Assessment & 
Randomization 
(0-14 days from 
implant)  Six Month Follow -
up 
(Day 180 to 210 
days after 
randomization)  Additional 
Visits  
Informed consent process, 
including informed consent 
signature [CONTACT_568]  X     
Inclusion/Exclusion  X     
Demographics  X     
Physical assessment   X  X  
Medical history  X     
Echo cardiography   X  X  
NYHA Class   X  X  
[ADDRESS_418650]   X  X  
Kansas City Cardiomyopathy 
Questionnaire  (KCCQ)   X  X  
Patient & Physician Global 
Assessments     X  
Cardiac medication s X X** X** X** X** 
RV and LV lead location    X   
Implanted d evice information    X   
Randomization – obtained via the 
EDC system    X*   
Device interrogation/ 
programming status    X X * 
Reportable AE’s, SAE’s and HF 
events   * * * * 
X = required; *=Data required only if the event occurred ; **= Only  changes to cardiac medications are required to be documented
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page [ADDRESS_418651] . 
Table 11-2 lists the data collection requirements at the enrollment visit.  
Table 11-2: Source Documentation Requirements – Enrollment Visit  
Data Collection Requirement  Retention of Original Source 
Documentation  
• Informed Consent Form and process, 
including informed consent and signature 
[CONTACT_568] 
• Inclusion/Exclusion Criteria  
• Demographics 
• Medical History  
• Cardiac Medication(s)  Investigational Center 
11.4. Pre-Implant Assessment  
The following tests may only be performed after the Enrollment Visit  and must be complete d 
< 30 days prior to the implant procedure : physical assessment, echocardiogram (Appendix 
27.1), six -minute walk test  (Appendix 27.2), and Kansas City Cardiomyopathy Questionnaire 
(Appendix 27.3).  
 Physical Assessment  
Physical presentation will be used to provide an assessment of the patient’s condition and changes in clinical symptoms.  Evaluation includes: 
• Resting heart rate  • NYHA C lass assessment  
• 12 lead  ECG* • Presenting symptoms  
• Blood pressure  • Height/weight 
 
* Analysis of the 12 lead ECG by [CONTACT_338646]: ventricular ra te, intrinsic PR 
interval, intrinsic QRS interval, and nature of interventricular conduction delay (left bundle branch block, right bundle branch block, or non -specific interventricular conduction delay).  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 26 of 67  
  • List of cardiac medications**  
The subject’s current NYHA Class must be determined based on Table 11 -3. 
 
Table 11-3: NYHA Classifications  
 
 Echocardiography 
Echocardiography will be used to assess cardiac function and structure. R ecordings of each 
echo session should be uploaded or mailed  to the Echocardiographic Core Laboratory within 
10 days of completion .  A complete echocardiography protocol may be found in Appendix 
27.1: Echocardiography Protocol.  
  Six-Minute Walk Test  
To assess tolerance of every -day physical activity, subject s are required to complete a six -
minute walk test. To perform this test, the subject  is encouraged to walk as far as possible  on 
a flat surface (e.g., clinic corridor) during a six -minute time period. The total distance 
traveled is measured (in feet or meters) and used for analysis.  Detailed instructions may be 
found in Appendix 27.2: Six -Minute Walk Test.  
 
Patient s with orthopedic limitations (e.g., arthritis or wheelchair/cane/scooter use), known 
non-cardiac comorbidities that prevent normal walking (e.g., emphysema or need for 
supplemental oxygen), or for whom there are safety concerns (e.g., angina) are excused from 
six-minute walk testing.  Inability to perform a six -minute walk due to medical reasons is not 
a deviation. Patients who complete a baseline six minute walk test but who cannot walk at 
least [ADDRESS_418652] but terminate it for 
 
** For study purposes, cardiac medications include : diuretics, ACE inhibitors/angiotensin receptor blockers, beta 
blockers, aldosterone antagonists, Class I/III antiarrhythmics, calcium channel blockers, anti -hypertensive 
drugs, and statins.  

C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 27 of 67  
  non-cardiovascular reasons or safety reasons will be excluded from testing of six -minute 
walk distance at the Six M onth Follow-Up.  
 
 Kansas City Cardiomyopathy Questionnaire  
The Kansas City Cardiomyopathy Questionnaire (KCCQ)  will be administered at  the P re-
Implant (baseline) Assessment  and again at the Six Month F ollow -Up visit. A detailed 
description of the questionnaire can be found in Appendix 27.3: Kansas City 
Cardiomyopathy Questionnaire. 
 
Table 11-4: S ource Documentation Requirements – Pre -Implant Assessment  
Data Collection Requirement  Retention of Original Source Documentation 
• Physical Assessment  
• NYHA Assessment  
• Cardiac Medication  Changes 
• Six-minute walk test  
• KCCQ  
• Reportable Adverse Events, Device 
Deficiencies, and Protocol Deviations, 
if applicable  Investigational Center 
• 12 lead ECG Retain at Investigational Center and upload to the EDC system  
• Echocardiogram  Retain at Investigational Center, copy uploaded 
or mailed  to Echocardiography Core Lab  
11.5. Post-Implant Assessment  and Randomization 
Recommended programming is DDD  or DDDR with a lower rate limit (LRL) of 60bpm 
throughout participation in the study. If programming is different from this recommendation for clinical circumstances, the rational shall be provided . The Post-I mplant A ssessment must 
occur 0-14 days after the implant procedure. Tasks to be performed at this visit include: 
• Documentation of device information, including manufacturer, model and serial number, and implant date (s) of the CRT -D device, RA lead, RV lead,  and LV lead  
 
• Pulse generator interrogation  with routine lead evalu ation of the  implanted RA, RV 
and LV leads in final programming configuration which includes: 
o Intrinsic sensing (mV)  
o Pacing impedance ( Ω) 
o Shock lead impedance ( Ω) 
o Pacing capture threshold (V /ms; the pulse width is at investigator discretion)  
o Pacing capture threshold, impedance, and PNS for any LV vector which meets 
criteria in 11.5.1 
 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 28 of 67  
  Note:  Patients must have functional RA, RV and LV leads. If one of t he leads is not 
functional, patients cannot continue in the study and must be withdrawn at this point. 
 
• RV and LV lead location and, if known, rationale for LV lead placement. Such 
information is typi[INVESTIGATOR_338622]-procedure fluoroscopy or post- implant chest X -rays, or obtained from the subject’s 
medical reco rd.  
o LV lead location should be defined as:   
 Anterior, anterolateral, lateral, posterolateral, or posterior  
 Basal, middle, or api[INVESTIGATOR_2855]  
o RV lead location should be defined as: apex, free wall, septal wall, RV outflow tract, or other  
 
• RV-LV timing assessment  with VectorGuide as defined in section 11.5.1 
• SmartDelay test results, if applicable  
• Randomization programming, if applicable 
• Save programmer interrogation session and specified reports to USB  
  RV-LV Timing Assessment  and LV Pacing Vector Selection  
VectorGuide must be utilized  to assess LV pacing vectors with the following technique:  
 
1. Identify  RV- LV timing for each LV electrode  using VectorGuide 
 
2. Identify the impedance for each LV pacing vector with RV- LV delay ≥ 70ms  using 
VectorGuide  
 
3. Assess p hrenic nerve stimulation (PNS) in any LV pacing vector with an RV- LV 
delay  ≥ 70ms  at an output of 7.5V using VectorGuide. PNS will be assessed as per 
standard of care, based on subject complaint (such as hiccups or twitching) and confirmed by [CONTACT_338647] a qualified HCP. The PNS threshold is defined as the first voltage step without PNS. 
a. Presence or absence of PNS and PNS threshold must be documented in the 
LV Vector Guide Report. 
 
4. Assess the pacing capture threshold in each LV pacing vector with an RV- LV delay ≥ 
70ms using VectorGuide . The pacing capture threshold for each LV pacing vector 
with an RV- LV delay ≥ 70ms must  be documented on the VectorGuide Report.  
a. The recommended maximum acceptable pacing capture threshold for any LV vector is 4.5V@0.5ms . 
b. It is recommended that any vector with an RV- LV delay ≥ 70ms with PNS 
have a PNS threshold  ≥3V above the pacing capture threshold.  
5. If there are multiple LV pacing vectors with an RV-LV delay  ≥ 70ms  that meet the 
above criteria, the final programmed LV pa cing vector can be programmed at the 
discretion of the investigator using the following criteria:  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page [ADDRESS_418653] to as sess for any reportable safety events.  
 
 
Figure 11-1 : Post -Implant Assessment  
 
. 
 

C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page [ADDRESS_418654] occur when the patient’s presenting rhythm is compatible with the SmartDelay algorithm.  
 Perfor m the randomization assignment via the EDC system. Randomization in the EDC 
cannot occur without entry of RV- LV timing in programmed LV pacing vector. Every 
reasonable attempt will  be made to have subjects blinded to their randomized treatment arm 
assignment throughout the trial.   Tasks to be performed after randomization  include:  
• SmartDelay test to obtain programming recommendations for the AV Delay and pacing chamber 
• Programming the device to the subject’s randomized treatment arm  
• Save interrogation session and specified reports to USB  
 Devices are required to be programmed according to this protocol.  
[IP_ADDRESS]. SmartDelay Test  
It is required to perform SmartDelay test for all subjects to obtain programming recommendations for the AV Delay and Pacing Chamber (s). LV offset should be set  to 0ms 
throughout the duration of the study. For step -by-step guidance on how to perform the 
SmartDelay test, please refer to Appendix 27.4.  
Record the following values from the SmartDelay test in the EDC system : 
• Sensed AV Delay (SAV) and Paced AV Delay (PAV)  
• Pacing Chamber (BiV or LV Only) 
 After running SmartDelay, copy settings without programming changes, print and save to USB the Settings Changes Report. This report will display recommended SAV, PAV, and Pacing Chamber.  If the SmartDelay test fails to complete, re -perform the test to obtain the recommended value. 
If the SmartDelay test was complete but not successful, the recommended value will be the nominal value used by [CONTACT_338648].   
[IP_ADDRESS]. Programming Based on Randomization Assignment 
Fixed AV Delay : If the subject is randomized to the Fixed AV Delay  treatment arm, the 
SAV and PAV values must be set to 120ms with BiV pacing.  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 31 of 67  
  SmartDelay AV Delay : If the subject is randomized to the SmartDelay  treatment arm, SAV, 
PAV, and pacing chamber  settings must be programmed according to the results of the 
SmartDelay  optimization  throughout participation in the study . The final AV Delay  
programming must  be cap tured on the  printed  Device Follow Up  Report .  
If the LV MultiSite Pacing feature is available in the implanted device, this feature must be 
turned OFF throughout the duration of the study.  
 
Table 11- 5: Source Document Requirements –  Post -Implant Assessment  and 
Randomization  
Data Collection Requirement  Retention of Original Source 
Documentation  
• Cardiac Medications Changes  
• RV and LV lead location  
• Reportable Adverse Events, Device Deficiencies, and Protocol Deviations, if 
applicable  Investigational Center  
• Device Follow Up Report  
• Settings Change Report (to capture SmartDelay suggested settings)  
• Arrhythmia Logbook 
• LV VectorGuide Report  
• Patient Data Report  Printed reports and electronic reports on USB retained at Investigational Center  
 
 
11.6. Six Month Follow -Up Visit  
Tasks to be performed at this visit include:  
 
• Pulse generator interrogation with routine lead evaluation on implanted RA, RV and 
LV leads which includes:  
o Intrinsic sensing (mV)  
o Pacing impedance ( Ω) 
o Shock lead impedance ( Ω) 
o Pacing threshold (V) (pulse width at physician discretion)  
• Counter information (%RA, %RV, %LV, %AT/AF) 
• RV-LV timing assessment with VectorGuide for each LV el ectrode  
• SmartDelay test results  
• Save interrogation session to USB  
 
A Device Settings Report should be printed prior to completing any device testing at the Six 
Month Follow -Up. The HCP completing these assessments must be blinded to the subject’s 
treatmen t arm  and should not have access to the patient’s randomization status or the EDC:   
• Physical Assessment  (refer to  11.4.1 ), including NYHA Class assessment  
• Echocardiogram  completed with programmed pacing therapy active ( Appendix 27.1)  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 32 of 67  
  • Six-minute  walk test (Appendix 27.2) 
• KCCQ (Appendix 27.3) 
• Patient Global Assessment  (11.6.2) 
• Physician Global Assessment  (11.6.2 ) 
 
The subject’s device may be programmed at the investigator’ s discretion once all study 
testing has been completed.  
 SmartDelay Test  
It is required to perform the SmartDelay test for all subjects to obtain programming 
recommendations for the AV Delay and Pacing Chamber(s). For step -by-step guidance on 
how to perform the SmartDelay test, please refer to Appendix 27.4.  
Record the following values from the SmartDelay in the EDC system:  
• Sensed AV Delay (SAV) and Paced AV Delay (PAV)  
• Pacing Chamber (BiV or LV Only) 
 
After running SmartDelay , copy settings without programming changes, print and save to 
USB the Settings Changes Report. This report will display recommended SAV, PAV, and Pacing Chamber.  
If the SmartDelay test fails to complete, re -perform the test to obtain the recommended value. 
If the SmartDelay tes t was complete but not successful, the recommended value will be the 
nominal value used by [CONTACT_338648]. 
 Quality of Life Global Assessment  
In addition to the KCCQ, quality of life will be assessed at six months using the Patient 
Global Assessment and Physician Global Assessment . This consists of two questions, one of 
which is directed to the physician who is examining the patient and the other question is directed to the patient to  address how well the patient is doing since enrol ling in the study.  
 
Figure 11-2 : Quality of Life Global Assessment 
Physician Global Assessment  Patient Global Assessment  
How is the patient’s clinical status today 
compared to his or her status at the time of pre-
implant assessment ? 
• Markedly improved  
• Moderately improved 
• Mildly improved  
• No change  
• Mildly worse  How do you feel today compared to how you felt 
when you started the study?  
• Very much better  
• Much better  
• A little better 
• No change  
• A little worse  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 33 of 67  
  • Moderately worse  
• Markedly worse  • Much worse  
• Very much worse 
 
Table 11- 6: Source Document Requirements –  Six Month Visit  
Data Collection Requirement  Retention of Original Source Documentation  
• Physical Assessment  
• NHYA Class Assessment  
• Cardiac Medication Changes  
• Six-minute walk test  
• KCCQ  
• Patient Global Assessment  
• Physician Global Assessment  
• Reportable Adverse Events, Device 
Deficiencies, and Protocol Deviations, 
if applicable  Investigational  Center  
• Echocardiogram  Retain at Investigational Center, copy uploaded 
or mailed  to Echocardiography Core Lab 
• Device Settings Report (printed prior 
to device testing)  
• Device Follow Up Report  (including 
counter information)  
• Settings Change Report  
• Arrhythmia Logbook 
• LV VectorGuide Report  Printed reports and electronic reports on USB retained at Investigational Center  
 
11.7. Additional  Follow -Up Visits  
Physician office visits, emergency room visits, out -patient hospi[INVESTIGATOR_6042], and 
hospi[INVESTIGATOR_338623] -up visit only if they are associated 
with system revision, device deficiency, reportable adverse event, protocol deviation or 
device programming change as listed below.  Other scheduled and unscheduled visits 
throughout the year (e.g., standard of care device checks) that do not meet these criteria are not required by [CONTACT_760] .   
 Changes in the following programming settings require an Additional Visit to be completed:  
• AV Delay  
• Pacing chamber (BiV pacing or LV only pacing)  
• LV pacing vector configuration selected at the P ost-Implant A ssessment  
• LV Offset  
• Pacing mode (e.g. DDD, VVI)  
• LRL  
• Any time the device counter is re set 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 34 of 67  
  o Date the counter is reset  
o Percent of RV and LV pacing prior to resetting the counter in subjects  
 
A rationale of the setting changes is required.  
 
The following document ation  is required:  
• Settings Changes Report  
• Combined Follow Up Report  
A summary of the source documentation required at the Additional Visit is described  Table 
11-7.  
Table 11- 7: Additional Follow -Up Visit Data Collection  
Data Collection  Retention of Original 
Source Documentation  
• Reportable Adverse Events, Device 
Deficiencies, and Protocol Deviations, if applicable  
• Cardiac Medication Changes  Investi gational  Center  
• Combined Follow Up Report  
• Settings Change Report  Printed reports and electronic 
reports on USB retained at Investigational Center  
 
 
11.8. Device Programming Outside of the Investigational Plan  
Once a subject is programmed to a  randomized treatment arm, every effort must be made to 
keep the subject’s device programmed per the required programming in this protocol. Any 
device reprogramming of AV Delay  change , including the reason for change, must be 
recorded as a protocol deviation and the clinical circumstances must be documented. After 
reprogramming to device settings outside of the required programming per protocol, subjects 
will remain in the assigned treatment arm until the end of the study to follow the methodology of intention- to-treat (ITT). Deviated programming does n’t qualify as reason for 
study withdrawal, and subjects will continue to be followed per the investigational plan. 
11.9. Study Completion  
Subject participation in the study is considered complete for the following reasons:  
• Study completion per protocol   
o A Six Month F ollow -Up visit has been recorded at least [ADDRESS_418655] an RV-LV delay ≥ 70ms on any electrode  (E1, E2, 
E3, E4) with a qualifying pacing vector  at the Post-Implant A ssessment  
• Death ( see 19.7 for reporting requirements ); 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 35 of 67  
  • Withdrawal  for reasons that include, but are not limited to:  
o Subject found not to meet eligibility criteria  
o Subject did not get randomized  
o Subject choice to withdraw consent  
o Device explanted and not replaced with a CRT -D system  
o VAD insertion or heart transplant  
o Investigator discretion  
o Lost to follow -up, despi[INVESTIGATOR_10094];  
o Three documen ted attempts to contact [CONTACT_423], including one certified 
letter, are required to declare a subject lost to follow up. 
11.10. Source Documents  
Original source documents are required to be retained at the center.  Where copi[INVESTIGATOR_338624], these shall be signed and dated by a member of the investigational site team with a statement that it is a true reproduction of the original source document.  
NOTE: If thermal paper from the device programmer was used for source documentation, photocopi[INVESTIGATOR_338625].  
12. Statistical Considerations  
12.1. Primary Endpoint 
The primary endpoint will compare the CRT response rates of randomize d subject s.  CRT 
response is defined by >15% decrease in LVESV from pre -implant baseline through 6 
months.  
 Hypotheses  
The following set of hypotheses will be used to evaluate the Primary Endpoint:  
H
o: p (SmartDelay)  ≤ p (Fixed)  
H1: p (SmartDelay)  > p (Fixed)  
 Where p represents the proportion of CRT responders.  Response is defined as a >15% decrease LVESV ([LVESV
6M – LVESV BL]/ LVESV BL < - 15%). 
 Sample Size  
An estimated [ADDRESS_418656] 436 patients 
are randomized or the number of required randomized subjects as de termined by [CONTACT_338649]- assessment. A total of 370 complete datasets at 6 months are required to 
sufficiently power the endpoint. 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 36 of 67  
  Sample size was calculated using the following assumptions:  
• Patient cohort = all randomized subjects ( RV-LV ≥ 70 ms ) 
• Effect size = 14% difference (based on ability to detect at least 75% of the 19% 
difference observed in SMART AV) 
• Estimated CRT response rate in Fixed AV Delay group = 53% 
• Randomization allocation = 1:1 
• Subject s contributing to analysis = 51% (60%*85%) of enrolled subjects  
o 60% of enrolled subjects with RV- LV ≥ 70 ms  
o 85% of randomized subject s with complete datasets at [ADDRESS_418657] s with RV- LV ≥ 70 ms  
• One-sided alpha = 2.5%  
The required sample size to sufficiently power the analysis evaluating a median cutoff is 
less than the sample size described above. 
 
 Statistical Methods  
Randomized subjects with paired LVESV data – baseline and 6 months – will be included in 
the analysis.  Subjects will be analyzed according to their randomization group.  To avoid 
making erroneous assumptions about incomplete/missing endpoint data, data from subjects with incomplete/missing data will not be imputed; therefore the statistical analysis of the 
Primary Endpoint will be a modified intention -to-treat analysis.  A chi -square test employing 
a one-sided alpha of 2.5% will compare the proportion of responders in the SmartDelay  
randomized group to the Fixed AV Delay  randomized group.  If the p-value is less than 0.05, 
the null hypothesis will be re jected.   
A pure intention -to-treat analysis, in which the incomplete/missing endpoint data is imputed 
and included in the analysis, may be performed as a sensitivity analysis.  
12.2. General Statistical Methods 
 Analysis Sets  
All subject s with paired data at base line and [ADDRESS_418658] (i.e., LVESV, subject  global assessment, etc. ).   
 Control of Systematic Error/Bias  
Subject s will be randomized to minimize subject selection bias. To eliminate the potential for 
a placebo effect to affect the Primary Endpoint results, the objective measure of LVESV was 
chosen.  Every attempt will be made to blind subject s to their randomized treatment 
assignment in order to minimize a placebo effect on qualitative analyses, such as quality of life.  To reduce the inter -observer variability that can occur with echocardiographic 
measurements, a core lab blinded to treatment assignment will be used.   
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 37 of 67  
  
 Number of Subjects per Investigative Site  
A maximum of 72 enrolled subjects will be allowed from an investigational site , equal to 
10% of the expected 726 subjects to be enrolled in the study. 
12.3. Additional Data Analyses  
 Other Endpoints/Measurements  
The following outcomes will be evaluated in addition to the Primary Endpoint analysi s, each 
comparing subjects according to their randomized groups: 
• LVESV as a continuous variable 
• Clinical Composite Endpoint  
o All-cause mortality  
o Heart failure events (as defined in Section  19.1 ) 
o NYHA Class  
o Quality of Life (Patient Global assessment instrument ) 
• Components of the Clinical Composite Endpoint 
• KCCQ  
• Left-ventricular ejection fraction (LVEF) 
 Tertiary/Exploratory Analyses 
The following tertiary analyses will be performed and considered exploratory in nature: 
• Six minute walk, compared between randomized groups.  
• Optimal cutoff analysis.  An RV -LV cutoff of 70 ms was used to identify which 
subjects will be randomized.  Analyses will be performed to find the optimal cutoff – 
greater than or equal to 70 ms – as determined by [CONTACT_26739].    
 Primary Endpoint Sensitivity Analyses  
The Primary Endpoint, in addition to the additional analyses listed above, w ill be evaluated 
using modified intention -to-treat methodology, in which subject s with complete datasets are 
evaluated according to their randomized treatment groups.  Sensitivity analyses include the following:  
• Pure intention- to-treat – Subject s are analy zed according to their randomized group 
and missing data is imputed via multiple imputation  
• On treatment – Subject s are analyzed according to the actual treatment received  
• Per protocol – Subjects are analyzed according to their randomized group, but limited to subject s that received the randomized assignment.  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page [ADDRESS_418659] half of the required 6 month datasets (N = 185) have been completed and 
reviewed by [CONTACT_50338], an interim sample size re- assessment will be performed.  The 
pooled and blinded response rate across both groups will be assessed in this interim sample 
size re-assessment cohort.  The observed rate will be weighted by [CONTACT_338650].  If the observed rate is less than the assumed rate, the number of patients required for randomization will be increased 
accordingly, up to a maximum of [ADDRESS_418660] will not be 
calculated, thereby [CONTACT_338651].   
There are no formal interim analyses planned to terminate the study for effectiveness of futility.  
 Subgroup Analyses  
The subgroups that will be evaluated include, but are not limited to, the following: 
• Age < 65 years vs. ≥ 65 years  
• Females vs. Males  
• Ischemic vs. Non -ischemic etiolog y 
• LBBB vs Non -LBBB  
• QRS < 150 ms vs. ≥ 150 ms  
• Api[INVESTIGATOR_249633]. Non- api[INVESTIGATOR_338626]  (for each RV lead and LV lead placement)  
• NYHA Class I/II vs. III/IV  
• SmartDelay recommended programming  
o LV only vs. biventricular (BiV) pacing 
o AV Delay (equal to 120±20 ms vs. all others) 
 The interaction between the subgroup and randomized groups will be evaluated (e.g., gender by [CONTACT_91727]). Additionally, each subgroup will have the SmartDelay vs. Fixed comparison calculated separately (e.g., SmartDelay vs. Fixed evaluated in Females).  
 Multivariable Analyses  
Multivariate analyses will be performed using characteristics listed in Section 12.3.5 Error! 
Reference source not found. .  Additional covariates may also be considered.  The primary 
approach to multivariate modeling will be as follows: 
• Univariate to Multivariate:  Univariate modeling is first performed.  Significant covariates are considered for inclusion in the final multivariate model.  Non -
significant covariates are dropped from consideration.  A model selection technique (e.g., best subsets, stepwise regression) is then employed to determine the final multiv ariate model.  
Additionally, the following multivariate modeling approaches may be used: 
• Recursive Partitioning:  The overall population is classified into mutually exclusive 
subgroups in the form of a decision tree.  Each characteristic is dichotomized, though 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 39 of 67  
  the cutpoint used for dichotomization is determined by [CONTACT_338652].  
To avoid potential problems with model overfitting, methods related to recursive partitioning – such as random forests or stochastic gradient boosting – may be 
emplo yed. 
• Risk Score:  Characteristics considered to be associated with CRT Response – determined by [CONTACT_338653]/medical experts – will be combined and converted into a score that can be used to predict CRT Response.   
 Changes  to Planned Analyses  
Any changes to the planned statistical analyses made prior to performing the analyses will be documented in the Statistical Analysis Plan approved prior to  performing the analyses. 
Changes from the planned statistical methods after performing the analyses will be documented in the clinical study report along with a reason for the change. 
13. Data Management 
13.1. Data Collection, Processing, and Review 
Subject data will be recorded in a limited access secure electronic data capture (EDC) system.  
The clinical database will reside on a production server hosted by [CONTACT_5730] . All changes 
made to the clinical data will be captured in an electronic audit trail and available for review by [CONTACT_230025]. The associated RAVE software and database have been designed to meet regulatory compliance for deployment as part of a validated system compliant with laws and regulations applicable to the conduct of clinical studies pertaining to the use of electronic records and signatures. Database backups are performed regularly.  
The Investigator provides his/her electronic signature [CONTACT_5760] (eCRFs) in compliance with local regulations. A written signature [CONTACT_5761] [CONTACT_1295]. Changes to data previously submitted to the sponsor require a new electronic signature [CONTACT_3265] [CONTACT_5732]. 
Visual and/or electronic data review will be performed to identify possible data 
discrepancies. Manual and/or automatic queries will be created in the EDC system and will be issued to the site for appropriate response. Site staff will be responsible for resolving all queries in the database.  
13.2. Data Retention 
The Principal Investigator [INVESTIGATOR_022]/her designee or Investigational site will maintain, at the 
investigative site, all essential study documents and source documentation that support the data collected on the study subjects in compliance with ICH/GCP guidelines.  Documents must be ret ained for at least [ADDRESS_418661] elapsed since the formal discontinuation of the clinical investigation of 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418662]. These documents will be retained for a longer period of time  by [CONTACT_338654]/regional/ local regulations.  
The Principal Investigator [INVESTIGATOR_022]/her designee will take measures to ensure that these 
essential documents are not accidentally damaged or destroyed. If for any reason the 
Principal Investigator [INVESTIGATOR_022]/her designee withdraws responsibility for maintaining these essential documents, custody must be transferred to an individual who will assume responsibility and BSC must receive written notification of this custodial chang e. Sites are 
required to inform [LOCATION_011] Scientific in writing where paper or electronic files are maintained 
in case files are stored off site and are not readily available.  
13.3. Core Laboratories  
All echocardiography measurements will be performed by [CONTACT_338655]. The Echocardiography Core Laboratory determined values will be used for the Primary Endpoint analysis as well as all echo related additional analyses.  
14. Amendments  
If a protocol revision is necessary which affects the rights, safety or welfare of the subject or scientific integrity of the data, an amendment is required. Appropriate approvals (e.g., IRB/EC) of the revised protocol must be obtained prior to implementation.  
15. Deviations  
An Investigator must not make any changes or deviate from this protocol, except to protect the life and physical well -being of a subject in an emergency. An investigator shall notify the 
sponsor and when applicable the reviewing IRB/EC of any deviation from the investigational 
plan to protect the life or physical well- being of a subject in an emergency, and those 
deviations which affect the scientific integrity of the clinical investigation. Such notice shall be give n as soon as possible, but no later than [ADDRESS_418663] be documented and reported to the sponsor using the deviation CRF in the 
EDC system.  Sites may also be required to report deviations to the IRB/EC, per local 
guidelines and government regulations.  
Deviations will be reviewed and evaluated on an ongoing basis and, as necessary, appropriate 
corrective and preventive actions (including IRB notification, site re-training, or site 
discontinuation/termination ) will be put into place by [CONTACT_456].  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418664] market clinical follow up guidelines and will 
follow the applicable sections of ISO [ZIP_CODE]  (Clinical Investigation of Medical Devices for 
Human Subjects – Good Clinical Practice), the relevant parts of the ICH Guidelines for Good 
Clinical Practices, ethical principles that have their origins in the Declaration of Helsinki, and pertinent individual country laws and regulations. The study shall not begin until the required approval/favorable opi[INVESTIGATOR_5698]/EC and/or regula tory authority has been obtained, 
if appropriate. Any additional requirements imposed by [CONTACT_1201]/EC or regulatory authority shall be followed, if appropriate.   
16.2. Investigator Responsibilities  
The Principal Investigator [INVESTIGATOR_338627], the clinical investigation plan/, ISO [ZIP_CODE], ethical principles that have their origins in the Declaration of Helsinki, any conditions of approval imposed by [CONTACT_941] r eviewing IRB/EC, and prevailing local and/or 
country laws and/or regulations, whichever affords the greater protection to the subject.  
The Principal Investigator’s responsibilities include, but are not limited to, the following.  
• Prior to beginning the study, sign the Clinical Study Agreement and comply with the 
Investigator responsibilities as described in such Agreement.   
• Prior to beginning the study, sign the Protocol Signature [CONTACT_71660]/her 
agreement to conduct the study in accordance with t he protocol. 
• Provide his/her qualifications and experience to assume responsibility for the proper 
conduct of the study and that of key members of the site team through up- to-date 
curriculum vitae or other relevant documentation and disclose potential conf licts of 
interest, including financial, that may interfere with the conduct of the clinical study or 
interpretation of results.  
• Make no changes in or deviate from this protocol, except to protect the life and physical well-being of a subject in an emergenc y; document and explain any deviation from the 
approved protocol that occurred during the course of the clinical investigation.  
• Create and maintain source documents throughout the clinical study and ensure their availability with direct access during monitoring visits or audits; ensure that all clinical-investigation- related records are retained per requirements.  
• Ensure the accuracy, completeness, legibility, and timeliness of the data reported to the 
sponsor in the CRFs and in all required reports.  
• Record, report, and assess (seriousness and relationship to the device/procedure) every 
adverse event as applicable per the protocol  and observed device deficiency. 
• Report to sponsor , per the protocol requirements, all SAEs and device deficiencies that 
could have led to a SADE  and potential/[LOCATION_003]DE or UADE . 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page 42 of 67  
  • Report to the IRB/EC and regulatory authorities any SAEs and device deficiencies that 
could have led to a SADE and potential/[LOCATION_003]DE or UADE , if required by [CONTACT_322649]/EC, and supply BSC with any additional requested information related to the safety reporting of a particular event.  
• Allow the sponsor to perform monitoring and auditing activities, and be accessible to the 
clinical research monitor or auditor and respond to questions during monitoring visits or 
audit(s). 
• Allow and support regulatory authorities and the IRB/EC when performing auditing 
activities.  
• Ensure that informed consent is obtained in accordance with applicable laws, this protocol and local IRB/EC requirements.  
• Provide adequate medical care to a subject during and after a subject’s participation in a clinical study in the case of adverse events, as described in the Informed Consent Form (ICF).  
• Inform the subject of the nature and possible cause of any adverse events experienced.  
• Inform the subject of any new significant findings occurring during the clinical investigation, including the need for additional medical care that may be required. 
• Provide the subject with well- defined procedures for possible emergency situations 
related to the clinical study, and make the necessary arrangements for emergency treatment, including decoding procedures for blinded/masked clinical investigations, as needed. 
• Ensure that clinical medical records are clearly marked to indicate that the subject is 
enrolled in this clinical study. 
• Ensure that, if appropriate, subjects enrolled in the clinical investigation are provided 
with some means of showing their participation in the clinical investigation, together with identification and compliance information for concomitant treatment measures (contact [CONTACT_5735]). 
• Inform, with the subject’s approval or when required by [CONTACT_2091], the subject’s personal physician about the s ubject’s participation in the clinical investigation.  
• Make all reasonable efforts to ascertain the reason(s) for a subject’s premature 
withdrawal from clinical investigation while fully respecting the subject’s rights.  
• Ensure that an adequate investigation site team and facilities exist and are maintained and 
documented during the clinical investigation. 
• Ensure that maintenance and calibration of the equipment relevant for the assessment of the clinical investigation is appropriately performed and documente d, where applicable. 
 Delegation of Responsibility  
When specific tasks are delegated by [CONTACT_2413], including  but not limited to conducting 
the informed consent process, the Principal Investigator [INVESTIGATOR_338628] 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver D 
                                                                                                                       Page [ADDRESS_418665]/ Ethics Committee  
Prior to gaining Approval- to-Enroll status, the investigational site will provide to the sponsor 
documentation verifying that their IRB/EC is registered or that registration has been submitted to the appropriate agency, as applicable according to national/regulatory requirements.   
A copy of the written IRB/EC and/or competent authority approval of the protocol (or 
permission to conduct the study) and Informed Consent Form, must be received by [CONTACT_71646]/equipment. Prior approval must also be obtained for other materials related to subject recruitment or which will be provided to the subject.  
Annual IRB/EC approval and renewals will be obtained throughout the duration of the study as required by [CONTACT_5737]/country or IRB/EC requirements. Copi[INVESTIGATOR_5699]’s reports and the IRB/EC continuance of approval must be provided to the sponsor.  
16.4. Sponsor Responsibilities 
All information and data sent to BSC concerning subjects or their participation in this study 
will be considered confidential by [CONTACT_71640]. Only authorized BSC personnel or a BSC representative including, but not limited to Contract R esearch O rganization (CRO) will have 
access to these confidential records. Authorized regulatory personnel have the right to inspect 
and copy all records pertinent to this study. Study data collected during this study may be 
used by [CONTACT_113644], publication, and to support future research and/or other business purposes. All data used in the analysis and reporting of this study will be without identifiable reference to specific subject name.  
[LOCATION_011] Scientific will keep subject s’ identifiable health information confidential in 
accordance with all applicable laws and regulations.  [LOCATION_011] Scientific may use subjects’ health information to conduct this research, as well as for additional purposes, such as overseeing and improving t he performance of its device, new medical research and proposals 
for developi[INVESTIGATOR_71613], and other business purposes. Information received during the study will not be used to market to subjects; subject names will not be placed on any mailing lists or sold to anyone for marketing purposes.  
 Role of [LOCATION_011] Scientific Representatives  
[LOCATION_011] Scientific personnel can provide technical support to the investigator and other health care personnel (collectively HCP) as needed during implant, testing required by [CONTACT_760], and follow-ups. Support may include HCP training, addressing HCP questions, or providing clarifications to HCPs concerning the operation of BSC equipment/devices (including programmers, analyzers, and other support equipment). 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418666] to accomplish requested activities. 
Typi[INVESTIGATOR_71614].  
• Interrogating the device or programming device parameters to investigator -requested 
settings as well as operating investigational equipment  
• Performing lead diagnostic testing using a Pacing System Analyzer or programmer to 
obtain pacing and sensing thresholds and impedance measurements  
• Clarifying device behavior, operation or diagnostic output as requested by [CONTACT_71648]  
• Assisting with the collection of study data from Pacing System Analyzers, programmers, 
and other equipment  
• Entering technical data on technical source form as long as the responsible investigator  
verifies and signs the completed worksheet  
• Print out programming reports directly from the clinician programmer and provide 
original to clinical site as source documentation  
• Provide technical expertise/support to subjects during office visits and/or during 
teleconference calls/electronic communications with the principal invest igator or their 
delegated site staff and the subject.  
 
In addition, BSC personnel may perform certain activities to ensure study quality. These 
activities may include the following.  
• Observing testing or medical procedures to provide information relevant t o protocol 
compliance  
• Reviewing collected data and study documentation for completeness and accuracy  
[LOCATION_011] Scientific personnel will not do the following.  
• Practice medicine  
• Provide medical diagnosis or treatment to subjects  
• Discuss a subject’s condition or treatment with a subject without the approval and 
presence of the investigator  
• Independently collect critical study data (defined as primary or secondary endpoint data)  
• Enter data in electronic data capture systems or on paper case report forms  
16.5. Insuranc e  
Where required by [CONTACT_5737]/country regulation, proof and type of insurance coverage, by [CONTACT_142219]. 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418667] the study safely and effectively. The Principal Investigator/institution guarantees direct access to original source documents by [CONTACT_5724], their designees, and appropriate regulatory authorities.  
The study may also be subject to a quality assurance audit by [CONTACT_5742], as well as 
inspection by [CONTACT_4708]. It is important that the  Principal  Investigator 
[INVESTIGATOR_5701]- site monito ring visits or audits and that 
sufficient time is devoted to the process.  
18. Potential Risks and Benefits 
18.1. Anticipated Adverse Events  
The following anticipated adverse events (AE) have been identified for anyone receiving a CRT -D system . 
Table 18- 1-1: Potential Adverse Events for Implantation of a Pulse Generator and/ or Lead 
System Implants  
Potential Adverse Events for Implantation of a Pulse Generator and/ or Lead System*  
Air embolism   Lead dislodgment   
Allergic reaction   Lead fracture   
Bleeding   Lead insulation breakage or abrasion   
Bradycardia  Lead perforation  
Cardiac tamponade   Lead tip deformation and / or breakage   
Chronic nerve damage   Local tissue reaction  
Component failure   Loss of capture  
Conductor coil fracture  Myocardial Infarction (MI)  
Death   Myocardial necrosis  
Elevated thresholds   Myocardial trauma (e.g., tissue damage, 
valve damage)  
Erosion   Myopotential sensing   
Excessive fibrotic tissue growth  Oversensing / undersensing   
Extracardiac stimulation (muscle/ nerve 
stimulation)  Pacemaker -mediated tachycardia (PMT) 
(Applies to dual -chamber devices only.)  
Failure to convert an induced arrhythmia  Pericardial rub, effusion   
Fluid accumulation  Pneumot horax  
Foreign body rejection phenomena   Pulse generator migration  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 46 of 67  
  Potential Adverse Events for Implantation of a Pulse Generator and/ or Lead System*  
Formation of hematomas or seromas   Shunting current during defibrillation with 
internal or external paddles  
Heart block   Syncope  
Heart failure following chronic RV api[INVESTIGATOR_338629], which include 
acceleration of arrhythmias and early, 
recurrent atrial fibrillation   
Inability to defibrillate or pace  Thrombus, thromboemboli  
Inappropriate therapy (e.g., shocks, and 
antitachycardia pacing [ATP] where 
applicable, pacing ) Valve damage  
Incisional pain   Vasovagal response  
Incomplete lead connection with pulse 
generator   Venous occlusion  
Infection including endocarditis  Venous trauma (e.g. perforation, dissection, 
erosion)  
Insulating myocardium during 
defibrillation with internal or external 
paddles  Worsening heart failure  
From the DYNAGEN, INOGEN, ORIGEN, INCEPTA, ENERGEN, PUNCTUA, TELIGEN Physician’s Technical Manual Oct 01, 2015; Part Number: 359403- 002 
 Patients may develop psychological intoleranc e to a pulse generator system and may 
experience the following:  
• Dependency  
• Depression  
• Fear of premature battery depletion  
• Fear of shocking while conscious  
• Fear that shocking capability may be lost  
• Imagined shocking  
• Fear of device malfunction  
18.2. Anticipated Adverse Device Effects  
Adverse Device Effects that are part of the listing in the previous  section are to be considered 
Anticipated Device Effects.  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418668] (without 
electrocardiogram monitoring) has been performed in thousands of subject s with HF or 
cardiomyopathy17,18,19   without serious adverse events. Moreover, risks can be minimized by 
[CONTACT_338656]: performing the test in a location where a rapid, 
appropriate response to an emergency is possible with a crash cart in a near known location; a technician certified in cardiopulmonary resuscitatio n with a minimum of Basic Life 
Support
20; it is up to the physician ordering the test to decide whether physician attendance at 
a specific test is required as physicians are not required to be present at all tests.  
Some addi tional risks may apply to those subject s for which the SmartDelay test is run.  
Tachycardia  therapy is disabled during SmartDelay optimization. The SmartDelay test also 
temporarily switches to a DDD mode of pacing with a lower rate limit of 40ppm and an AV Delay of 400ms. Any subject with symptomatic bradycardia  may be affecte d.  
18.4. Risk Minimization Actions  
Additional risks may exist. Risks can be minimized through compliance with this protocol, performing procedures in the appropriate hospi[INVESTIGATOR_84365], adherence to subject selection criteria, close monitoring of the subject' s physiologic status during research 
procedures and/or follow -ups and by [CONTACT_113646].  
18.5. Anticipated Benefits  
There may be no additional benefit to the subject  due to the study specific progr amming . 
However, medical science and future patients may benefit from their participation in this clinical study. If there is a superior or inferior arm, the subjects can be programmed at the conclusion of the study to the best programming suitable to thei r needs.  
18.6. Risk to Benefit Rationale  
The implantable device systems and accessories used for this clinical study will be commercially available and are considered to be standard of care for patient s indicated for 
such implants. The risks involved with subje ct participation in this study are essentially the 
same as those for patients not participating in the study.  
19. Safety Reporting  
19.1. Reportable Events by [CONTACT_338657]:  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 48 of 67  
  • All Serious Adverse Events  
• All Device Related Adverse Events  
o Events listed in the arrhythmia logbook should be reported only if determined 
to be clinical significant by [CONTACT_1755]/or delegated site staff (i.e. 
ATR, PMT, etc.)  
o All arrhythmias which received  inappropriate shock therapy as identified by a study investigator must be reported  
• All S erious Adverse Device Events  
• All Device Deficiencies  
• Unanticipated Adverse Device Effects/Unanticipated Serious Adverse Device Effects  
• All Heart Failure  (HF)  Related Events:  
An adverse event is deemed as a HF Event if the primary cause is HF and either of  
following conditions is met:  
o Subject is admitted and discharged with a calendar date change.  
o Subject is not hospi[INVESTIGATOR_338630], inotropes, vasodilators, other parenteral therapy, or aquapheresis.  
For Event reporting the medical diagnosis must be reported. In case the diagnosis is not 
available, individual symptoms can be reported to fulfill reporting timelines. If a diagnosis becomes available at a later stage, it must be added to the reported event.  
If it is unclear whether or not an event fits one of the above categories, or if the event cannot be isolated from the device or procedure, it should be submitted as an adverse event and/or device deficiency.  
Any AE event required by [CONTACT_760] , experienced by [CONTACT_313760] (as defined in study subject classification 
section), whether during or subsequent to the procedure, must be recorded in the eCRF. 
Underlying diseases are not reported as AEs unless there is an increase in severity of 
frequency during the course of the investigation. Death should not be reported as an SAE, but 
should be reported as an outcome of an SAE and only one SAE should have the outcome documented as fatal (see Table 19- 1 for AE definitions).  
Refer to Section 18 for the known risks associated with the study device(s).  
19.2. Definitions and Classification  
Adverse event definitions are provided in Table 19-1. Administrative edits were made on the 
definition of serious adverse event from ISO 14155and MEDD EV 2.7/3 for clarification 
purposes . Reportable events are defined in Section 19.1. 
 
Table 19-1: Safety Term Definitions  
Term  Definition  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 49 of 67  
  Table 19-1: Safety Term Definitions  
Term  Definition  
Adverse Event (AE)  
 
Ref: ISO [ZIP_CODE] 
 
Ref: MEDDEV 2.7/[ADDRESS_418669] clinical signs (including an abnormal laboratory finding) in 
subjects, users or other persons, whether or not related to the investigational 
medical device.   
NOTE 1: This includes events related to the investigational medical device 
or comparator.  
NOTE 2: This definition includes events related to the procedures involved.  
NOTE 3: For users or other persons, this definition is restricted to events 
related to t he investigational medical device.  
Adverse Device Effect (ADE)  
 
Ref: ISO [ZIP_CODE]  
Ref: MEDDEV 2.7/3   Adverse event related to the use of an investigational medical device  
NOTE 1: This includes any adverse event resulting from insufficiencies 
or inadequa cies in the instructions for use , the deployment, the 
implantation, the installation, the operation, or any malfunction of the 
investigational medical device.  
NOTE 2: This de finition includes any event resulting from use error or 
intentional  abnormal use  of the investigational medical device.  
Serious Adverse Event (SAE)  
 
Ref: ISO [ZIP_CODE] 
 
Ref: MEDDEV 2.7/3  Note: This definition meets  the reporting objectives  and requirements of  
ISO [ZIP_CODE]  and  MEDDEV 2.7/3.  
Adverse event that:  
• Led to death,  
• Led to  serious deterioration in the health of the subject  as defined by  
[CONTACT_5640] : 
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or  
3) in-patient hospi[INVESTIGATOR_113616] , or 
4) medical or surgical intervention to prevent life -threatening illness  
or injury or permanent impairment to a body structure or a body 
function 
• Led to fetal distress , fetal death, or a congenital abnormality or birth 
defect.  
NOTE 1: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure required by [CONTACT_5745], without a serious 
deterioration in health, is not considered a serious a dverse event.  
Serious Adverse Device Effect 
(SADE)  
 
Ref: ISO [ZIP_CODE] 
 
Ref: MEDDEV 2.7/[ADDRESS_418670] (UADE)  
 
Ref: [ADDRESS_418671], 
problem, or death was not previously identified in nature, severity, or degree of incidence in the investigatio nal plan or application (including a 
supplementary plan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 50 of 67  
  Table 19-1: Safety Term Definitions  
Term  Definition  
 of subjects.   
Unanticipated Serious Adverse 
Device Effect ([LOCATION_003]DE)  
 
Ref: ISO [ZIP_CODE] 
 
Ref: MEDDEV 2.7/[ADDRESS_418672] which by [CONTACT_5942], incidence, severity, or outcome has not been identified in the current version of the risk analysis 
report.  
NOTE 1 : Anticipated serious adverse device effect (ASADE) i s an effect 
which by [CONTACT_5942], incidence, severity or outcome has been identified in the 
risk analysis report.  
Device Deficiency  
 
Ref: ISO [ZIP_CODE] 
 
Ref: MEDDEV 2.7/3  A inadequacy of a n investigational  medical device related to  its identity, 
quality, durability, reliability, safety or performance.  This may include 
malfunctions, use error, or inadequacy in the information supplied by [CONTACT_13989].  
 
Abbreviations: EC=Ethics Committee; IRB=Institutional Review Board  
19.3. Relationship to Study Device(s)  
The Investigator must assess the relationship of the AE to the study device or procedure . See 
criteria in  Table 19- 2:  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 51 of 67  
  Table 19-2: Criteria for Assessing Relationship of Study Device  or Procedure  to Adverse Event  
Classification  Description  
Not Related  Relationship to the device or procedures can be excluded when:  
- the event is not a known side effect of the product category the device belongs to or 
of similar devices and procedures;  
- the event has no temporal relationship with the use of the investigational device or 
the procedures;  
- the serious event does not follow a known response pattern to the medical device (if 
the response pattern is previously known) and is biologically implausible;  
- the discontinuation of medical device application or the reduction of the level of 
activation/exposure - when clinically feasibl e – and reintroduction of its use (or 
increase of the level of activation/exposure), do not impact on the serious event;  
- the event involves a body- site or an organ not expected to be affected by [CONTACT_272627]; the serious event can be attribute d to another cause (e.g. an underlying  
or concurrent illness/ clinical condition, an effect of another device, drug, treatment or 
other risk factors);  
- the event does not depend on a false result given by [CONTACT_272628], whe n applicable; harms to the subject are not clearly due to use error;  
- In order to establish the non -relatedness, not all the criteria listed above might be 
met at the same time, depending on the type of device/procedures and the serious 
event.  
Unlikely Related  The relationship with the use of the device seems not relevant and/or the event can be 
reasonably explained by [CONTACT_5748], but additional information may be obtained.  
Possibly Related  The relationship with the use of the investigationa l device is weak but cannot be ruled 
out completely. Alternative causes are also possible (e.g. an underlying or concurrent illness/ clinical condition or/and an effect of another device, drug or treatment). Cases 
were relatedness cannot be assessed or no information has been obtained should also 
be classified as possible.  
Probably Related  The relationship with the use of the investigational device seems relevant and/or the 
event cannot reasonably explained by [CONTACT_5748], but additional information may 
be obtained.  
Causal Relationship  The serious event is associated with the investigational device or with procedures beyond reasonable doubt when: 
- the event is a known side effect of the product category the device belongs to or of 
similar devices and pr ocedures;  
- the event has a temporal relationship with investigational device use/application or 
procedures;  
- the event involves a body- site or organ that  
o the investigational device or procedures are applied to;  
o the investigational device or procedure s have an effect on;  
- the serious event follows a known response pattern to the medical device (if the 
response pattern is previously known);  
- the discontinuation of medical device application (or reduction of the level of 
activation/exposure) and reintroduction of its use (or increase of the level of 
activation/exposure), impact on the serious event (when clinically feasible);  
- other possible causes (e.g. an underlying or concurrent illness/ clinical condition 
or/and an ef fect of another device, drug or treatment) have been adequately ruled out;  
- harm to the subject is due to error in use;  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 52 of 67  
  Table 19-2: Criteria for Assessing Relationship of Study Device  or Procedure  to Adverse Event  
Classification  Description  
- the event depends on a false result given by [CONTACT_5749], when applicable;  
- In order to establish the relatedness, not all the criteria listed above might be met at 
the same time, depending on the type of device/procedures and the serious event.  
 
19.4. Investigator Reporting Requirements  
The communication requirements for reporting to BSC are as shown in  Table 19- 3. 
Adverse events must always be reported through the EDC system for SMART CRT. 
However, in the case of any issues where alternative method of reporting is necessary (i.e. the EDC system is not available), please report the adverse event to [LOCATION_011] Scientific by [CONTACT_313761]:  
 [EMAIL_6567]  
 
Table 19-3: Investigator Reporting Requirements   
Event Classification  Communication Method  Communication Timeline post -market 
studies**  
(MEDDEV 2.12/2 :   
GUIDELINES ON A MEDICAL DEVICE 
VIGILANCE SYSTEM ) 
Unanticipated Adverse 
Device Effect / Unanticipated 
Serious Adverse Device Effect  
 Complete AE eCRF page with all available new and updated information.  
 • Within [ADDRESS_418673] becoming 
aware of the event.  
• Terminating at the end of the study  
Serious Adverse Event  Complete AE eCRF page with 
all available new and updated information.  • Within 10 business days after becoming aware of the event or as per local/regional regulations.  
• Reporting required through the end of 
study 
Provide all relevant source 
documentation (unidentified) for reported event upon request of the sponsor  • When documentation is available  
Serious Adverse Device Effects  Complete AE eCRF  page with 
all available new and updated information.  • Within [ADDRESS_418674] 
becoming aware of the event or as per 
local/regional regulations.  
• Reporting required through the end of 
the study 
Provide all relevant source • When documentation is available  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 53 of 67  
  Table 19-3: Investigator Reporting Requirements   
Event Classification  Communication Method  Communication Timeline post -market 
studies**  
(MEDDEV 2.12/2 :   
GUIDELINES ON A MEDICAL DEVICE 
VIGILANCE SYSTEM ) 
documentation (unidentifie d) 
for reported event  
Device Deficiencies 
(including but not limited to failures, malfunctions, and product nonconformities)  
Note:  Any Investigational 
Device Deficiency that might have led to a serious adverse event if a) suitable action had 
not been taken or b) 
intervention had not been 
made or c) if circumstances 
had been less fortunate is 
considered a reportable event.  
 Complete Device Deficiency 
eCRF  with all available new 
and updated information.  • Within [ADDRESS_418675] 
becoming aware of the event. Reporting 
required through the end of the study  
Adverse Event including Adverse Device Effects  Complete AE eCRF page, which contains such information as date of AE, 
treatment of AE resolution, 
assessment of seriousness and 
relationship to the device.  • In a timely manner  (e.g. recommend 
within 30 business days) after becoming aware of the information 
• Reporting required through the end of 
study 
Abbreviations: AE=adverse event; CRF=case report for m; IDE=Investigational Device Exemption; 
UADE= unanticipated adverse device effect   
19.5. [LOCATION_011] Scientific Device Deficiencies 
All device deficiencies (including but not limited to failures, malfunctions, use errors, 
product nonconformities, and inadequacy in the information supplied by [CONTACT_3455] ) 
will be documented and reported to BSC. If possible, the device(s) should be returned to BSC for analysis. Device failures and malfunctions should also be documented in the subject’s medical record.  
Device deficiencies ( including but not limited to failures, malfunctions, and product 
nonconformities ) are not adverse events. However , an adverse event that results from a 
device failure or malfunction, would be recorded as an adverse event on the appropriate 
eCRF.  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418676] led to a serious adverse event if a) suitable action 
had not been taken or b) interve ntion had not been made or c) if circumstances had been less 
fortunate is considered a reportable event.  
19.6. Reporting to Regulatory Authorities / IRBs / ECs / Investigators  
BSC is responsible for reporting adverse event information to all participating Principal Investigators and regulatory authorities, as applicable. T he Principal Investigator [INVESTIGATOR_338631]/EC, and regulatory authorities of UADE and SAE as 
required by [CONTACT_5737]/regional regulations.. 
19.7. Subject Death Reporting  
A subject death during the study must be reported to [LOCATION_011] Scientific as soon as possible 
and, in any event, within ten (10) days or per local regulations of site notification . The 
center’s IRB/EC must be notified of any deaths in accordance with that cen ter’s IRB/EC 
policies and procedures. Whenever possible, the device should be interrogated and BSC system components (e.g., the device) should be removed intact and returned promptly to BSC RM for analysis.  
A detailed narrative (death letter) that provide s detailed information describing the 
circumstances surrounding the death  is required . A death narrative in the local language is 
acceptable, if accompanied by a translation in English. The details listed below should be addressed in the death narrative, i n order for BSC to understand the circumstance 
surrounding the death:    
• Date and time of death;  
• Place death occurred;  
• Immediate cause of death;  
• Rhythm at the time of death, if known (include any available documentation);  
• Whether or not the death was witnessed;  
• Whether the subject had worsening heart failure;  
• Any other circumstances surrounding the death;  
• Approximate time interval from the initiating event to death (temporal course) –  items to 
consider include, but are not limited to: information regarding last time subject was seen by 
[CONTACT_1697], last office visit, etc.  
• Investigator or co- Investigator signature [CONTACT_3670]. 
Other Source documents maybe requested at BSC . The Clinical Events Committee (CEC) 
must review information regarding subject deaths  if heart failure could not be ruled out as the 
cause of death . 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418677] or his/her legally authorized representative. The  Investigator is responsible for 
ensuring that Informed Consent is obtained prior to the use of any investigational devices, 
study- required procedures and/or testing, or data collection.  
The obtaining and documentation of Informed Consent must be in accor dance with the 
principles of the Declaration of Helsinki, ISO [ZIP_CODE], any applicable national regulations, and local Ethics Committee and/or Regulatory authority body, as applicable. The ICF must be accepted  by [CONTACT_113653] s delegate (e.g. CRO), and approved by [CONTACT_779]’s IRB/EC, or central 
IRB, if applicable.  
[LOCATION_011] Scientific will provide a study- specific template of the ICF to investigators 
participating in this study. The ICF template may be modified to meet the requirem ents of the 
investigative site’s IRB/EC.  Any modification requires acceptance from BSC prior to use of 
the form.  The ICF must be in a language understandable to the subject and if needed, BSC will assist the site in obtaining a written consent translation. Translated consent forms must also have IRB/EC approval prior to their use.  Privacy language shall be included in the body of the form or as a separate form as applicable.   
The process of obtaining Informed Consent shall  at a minimum include the follo wing steps, 
as well as any other steps required by [CONTACT_5751], rules, regulations and guidelines : 
• be conducted by [CONTACT_079] [INVESTIGATOR_5704],  
• include a description of all aspects of the clinical study tha t are relevant to the subject’s 
decision to participate throughout the clinical study, 
• avoid any coercion of or undue influence of subjects to participate,  
• not waive or appear to waive subject’s legal rights,  
• use native language that is non- technical and u nderstandable to the subject or his/her 
legal representative,  
• provide ample time for the subject to consider participation and ask questions if necessary,  
• ensure important new information is provided to new and existing subjects throughout the clinical stu dy.  
The ICF shall always be signed and personally dated by [CONTACT_338658], rules, regulations and guidelines and by [CONTACT_1755]/ or an authorized designee responsible for conducting the informed 
consent process. If a legal representative signs, the subject shall be asked to provide informed consent for continued participation as soon as his/her medical condition allows. The original signed ICF will be retained by [CONTACT_5753] a copy of the signed and dated document and any other written information must be given to the person signing the form.  
Failure to obtain subject consent will be reported by [CONTACT_338659] (e.g., FDA requirement is within 5 working days of learning 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 56 of 67  
  of such an event). Any violations of the informed consent process must be reported as 
deviations to the sponsor and local regulatory authorities (e.g. IRB/EC), as appropriate. 
If new information becomes avai lable that can significantly affect a subject's future health 
and medical care, that information shall be provided to the affected subject(s) in written form 
via a revised ICF or, in some situations, enrolled subjects may be requested to sign and date an addendum to the ICF. In addition to new significant information during the course of a 
study, other situations may necessitate revision of the ICF, such as if there are amendments 
to the applicable laws, protocol, a change in Principal Investigator, adminis trative changes, or 
following annual review by [CONTACT_1201]/EC. The new version of the ICF must be approved by 
[CONTACT_1201]/EC. Acceptance  by [CONTACT_338660]’s IRB/EC. The IRB/EC will determine th e subject population to be re -
consented.  
21. Committees 
21.1. Safety Monitoring Process  
To promote early detection of safety issues, the BSC Medical Safety group  will provide 
evaluations of safety events. A CEC will provide evaluations of all HF events  and deaths in 
which HF could not be eliminated as the cause . Success of this program requires dynamic 
collection of unmonitored data as soon as the event is reported. During regularly scheduled monitoring  activities , clinical research monitors will suppor t the dynamic reporting process 
through their review of source document and other data information.  The BSC Medical 
Safety group includes physicians with expertise in the necessary therapeutic and subject matter expertise to evaluate and classify the event s into the categories outlined above.  
21.2. Steering  Committee  
The Steering Committee is independent of [LOCATION_011] Scientific RM and provides oversight  for 
the overall conduct of the study with regard to protocol development, study progress, subject safety, and overall data quality and integrity.  
21.3. Clinical Events Committee  
A Clinical Events Committee (CEC) is an independent group of individuals with pert inent 
expertise that reviews and adjudicates predefined events  as reported by [CONTACT_2792]. 
For this study, c ommittee members will include a minimum of three practitioners with 
training in Electrophysiology (EP) and/ or Cardiology with the necessary therapeutic and subject matter expertise to adjudicate HF events and subject deaths. CEC responsibilities, qualifications, membership, and committee procedures are outlined in the CEC charter.  
 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 57 of 67  
  22. Suspension or Termination  
22.1 Premature Termination of the S tudy 
[LOCATION_011] Scientific Corporation reserves the right to terminate the study at any stage but 
intends to exercise this right only for valid scientific or administrative reasons and reasons related to protection of subjects.  Investigators, associated IRBs/ ECs, and regulatory 
authorities, as applicable, will be notified in writing in the event of study termination.  
22.1.1 Criteria for Premature Termination of the Study  
Possible reasons for premature study termination include, but are not limited to, the following.  
• The occurrence of unanticipated adverse device effects that present a significant or unreasonable risk to subjects enrolled in the study. 
• An enrollment rate far below expectation that prejudices the conclusion of the study.  
• A decision on the part of [LOCATION_011] Scientific to suspend or discontinue development of the device.  
22.2 Termination of Study Participation by [CONTACT_5717]/ EC Approval  
Any investigator, or IRB/ EC in the SMART CRT  Study may discontinue participation in the 
study or withdrawal approval of the study, respectively, with suitable written notice to [LOCATION_011] Scientific. Investigators, associated IRBs/ECs, and regulatory authorities, as applicable, will be notified in writing in the event of these occurrences.  
22.[ADDRESS_418678] Follow -up 
In the event of premature study termination a written statement as to why the premature termination has occurred will be provided to all participating sites by [CONTACT_5756]. The 
IRB/EC and regulatory  authorities, as applicable, will be notified. Detailed information on 
how enrolled subjects will be managed thereafter will be provided.  
In the event an IRB or EC terminates participation in the study, participating investigators, associated IRBs/ECs, an d regulatory authorities, as applicable, will be notified in writing. 
Detailed information on how enrolled subjects will be managed thereafter will be provided by [CONTACT_5756].  
In the event a Principal Investigator [INVESTIGATOR_113625], study responsibility 
will be transferred to a nother investigator, if possible. In the event there are no opportunities 
to transfer Principal Investigator [INVESTIGATOR_5705]; detailed information on how enrolled subjects will be managed thereafter will be provided by [CONTACT_5756].  
The Principal Investigator [INVESTIGATOR_022]/her designee must return all study- related documents and 
investigational product to [LOCATION_011] Scientific, unless this action would jeopardize the rights, safety, or welfare of the subjects.  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 58 of 67  
  22.4 Criteria for Suspending/Terminating a Study Site 
[LOCATION_011] Scientific Corporation reserves the right to stop the inclusion of subjects at a study 
site at any time after the study initiation visit if no subjects have been enrolled for a period 
beyond [ADDRESS_418679] e or severe protocol 
violations/noncompliance without justification and/or fails to follow remedial actions.  
In the event of termination of site  participation, all study devices and testing equipment, as 
applicable, will be returned to BSC unless this action would jeopardize the rights, safety or well-being of the subjects. The IRB/EC and regulatory authorities, as applicable, will be 
notified. All subjects enrolled in the study at the site will continue to be followed All subjects 
enrolled in the study at the site will continue to be followed according to the standard of care.  
The Principal Investigator [INVESTIGATOR_338632] -up visits unless 
BSC notifies the investigational site  otherwise.  
23. Publication Policy 
BSC requires disclosu re of its involvement as a sponsor or financial supporter in any 
publication or presentation relating to a BSC study or its results. BSC will submit study results for publication (regardless of study outcome) following the conclusion or termination of the study. [LOCATION_011] Scientific Corporation adheres to the Contributorship Criteria set forth in the Uniform Requirements of the International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org). In order to ensure the public disclosure of study re sults in a 
timely manner, while maintaining an unbiased presentation of study outcomes, BSC personnel may assist authors and investigators in publication preparation provided the following guidelines are followed.  
• All authorship and contributorship require ments as described above must be followed.  
• BSC involvement in the publication preparation and the BSC Publication Policy should be discussed with the Coordinating Principal Investigator(s) and/or Executive/Steering Committee at the onset of the project.  
• The First and Senior authors are the primary drivers of decisions regarding publication 
content, review, approval, and submission.  
24. Reimbursement and Compensation for Subjects  
[LOCATION_011] Scientific Corporation will purchase an insurance policy to cover the cost of potential 
health injury for study subjects , and if  required by [CONTACT_1289] .  
25. Bibliography  
1. Higgins SL HJ, Niazi IK, et al. . Cardiac resynchronization therapy for the treatment 
of hea rt failure in patients with intraventricular conduction delay and malignant ventricular 
tachyarrhythmias. J Am Coll Cardiol . 2003;42:1454- 1459. 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 59 of 67  
  2. Bristow MR SL, Boehmer J, et al. Cardiac -resynchronization therapy with or without 
an implantable defibrillator in advanced chronic heart failure. New Engl J Med 
2004;350:2140- 50. 
3. Moss AJ HW, Cannom DS, et al. Cardiac -resynchronization therapy for the 
prevention of heart -failure events. N Engl J Med 2009;361:1329- 38. 
4. M P. Proposal for a new clinical end poi nt to evaluate the efficacy of drugs and 
devices in the treatment of chronic heart failure. J Card Fail 2001;7:176- 82. 
5. Delgado V vBR, Bertini M, et al. Relative merits of left ventricular dyssynchrony, 
left ventricular lead position, and myocardial scar  to predict long -term survival of ischemic 
heart failure patients undergoing cardiac resynchronization therapy. Circulation 
2011;123:70 -78. 
6. Abraham WT LA, Hannon C, Prather W, Fieberg A. Results of the InSync III 
Marquis Clinical Trial (abstract). Heart  Rhythm 2005;2:S65.  
7. Rao RK KU, Schafer J, Viloria E, De Lurgio D, Foster E. Reduced ventricular 
volumes and improved systolic function with cardiac resynchronization therapy: a randomized trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing. Circulation. 2007;115:2136- 44. 
8. Baker JH TK, Pi[INVESTIGATOR_338633], et al. Optimization of interventricular delay in biventricular 
pacing: Results from the RHYTHM ICD V -V Optimization Phase Study. Heart Rhythm 
2005:P3- 96. 
9. Boriani G KW, Donal E, et al. A randomized double -blind comparison of 
biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the 
Biventricular versus Left Univentricular Pacing with ICD Back -up in Heart Failure Patie nts 
(B-LEFT HF) trial. Am Heart J 2010;159:1052- 8. 
10. Martin DO LB, Birnie D, et al. Investigation of a novel algorithm for synchronized 
left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: 
results of the adaptive CRT trial. Heart Rhythm . 2012;9:1807 -14. 
11. Abraham WT GD, Yu CM, et al. Results from the FREEDOM Trial (abstract). Heart 
Rhythm . 2010;7:2- 3. 
12. Ellenbogen KA GM, Meyer TE, et al. Primary results from the SmartDelay 
determined AV optimization:  a comparison to other AV delay methods used in cardiac 
resynchronization therapy (SMART -AV) trial: a randomized trial comparing empi[INVESTIGATOR_10477], 
echocardiography guided, and algorithmic atrioventricular delay programming in cardiac 
resynchronization therapy. Circulation. 2010;122:2660- 2668. 
13. Brugada Terradellas J DP, Brachmann J, et al. Clinical response to CRT with the 
SonR contractility sensor: The RESPOND -CRT Study.  . Oral presentation at Heart Rhythm 
Society, May 4 -7, 2016, San Francisco CA . 2016. 
14. Tomassoni G BJ, Corbisiero R, et al. Safety and efficacy of multipoint pacing in 
cardiac resynchronization therapy: The MultiPoint Pacing IDE Trial. Oral presentation at 
Heart Rhythm Society, May [ADDRESS_418680] ventricular electrical delay on AV 
optimization for cardiac resynchronization therapy. Heart Rhythm 2013;10:988- 93. 
16. Gold MR SJ, Ellenbogen KA, et al. Interventricular electrical delay is predictive of 
response to cardiac resynchroniz ation therapy. JACCEP . 2016;2:438- 47. 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418681] in patients with left ventricular dysfunction. SOLVD Investigators. JAMA . 
1993;270:1702- 1707. 
18.      Guya tt GH, Sullivan MJ, Thompson PJ et al. The six -minute walk: a new measure of 
exercise capacity in patients with chronic heart failure. Can Med Assoc J . 1985;132:919- 923. 
19.      Lipkin DP, Scriven AJ, Crake T et al. Six minute walking test for assessing e xercise 
capacity in chronic heart failure. Br Med J (Clin Res Ed) . 1986;292:653-  655. 
20.     Enright PL. The six -minute walk test. Respir Care. 2003;48:783- 785. 
  
 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 61 of 67  
   
26. Abbreviations  
Table 26- 1: Study Abbreviation 
Abbreviation  Term  
ADE  Adverse Device Effect  
AE Adverse Event  
AF Atrial Fibrillation  
AV AtrioVentricular  
BiV Biventricular  
BSC [LOCATION_011] Scientific Corporation  
CCE  Clinical Composite Endpoint  
CEC Clinical Events Committee  
CFR Code of Federal Regulations – excluding the endpoint sections  
CRF  Case Report Form  
CRO  Clinical Research Organization  
CRT  Cardiac Resynchronization Therapy  
CRT -D Cardiac Resynchronization Therapy – Defibrillator  
DD Device Deficiency  
DDD/DDDR  International Code for pacing mode: pacing site(s), sensing site(s), pacing mode, 
rate responsiveness  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
FCS Field Clinical Specialist  
FDA Food and Drug Administration 
GCP  Good Clinical Practice  
HCP  Healthcare Provider  
HF Heart Failure  
ICF  Informed Consent Form  
ICD Implantable Cardioverter Defibrillator  
IQRMP  Integrated Quality Risk Management Plan  
IRB Institutional Review Board  
IV Intravenous  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418682] Pacing Capture Threshold  
PG Pulse Generator  
PI [INVESTIGATOR_338634]  Q-Left Ventricular  
RA Right Atrium/ Atrial  
RM Rhythm Management  
RV Right Ventricle/ Ventricular  
RV-LV Right Ventricle -Left Ventricle  
RVs-LVs Right Ventricle sense -Left Ventricle sense  
SA Sensed Atrium  
SADE  Serious Adverse Device Effect  
SAE  Serious Adverse Event  
SAV Sensed AV  
US [LOCATION_002] of America  
UADE  Unanticipated Adverse Device Effect  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
UADE  Unanticipated Adverse Device Effect  
V Volts  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418683] be measured as part of the echocardiography exam at the pre -
implant and 6 month visits:  
 
• LVESV / LVEDV (by [INVESTIGATOR_203917]’s Method of Discs)  
• LVEF  
• Valve function: tricuspid, mitral & aortic regurgitation  
• LA volume  
 
The measurements should be taken at the Six Month Follow -Up visit with pacing therapy 
active.  
 Digitally store data in a DICOM format then copy to a CD -R. Maintain a copy of the study 
CD-R at the site  and either send or upload a copy to the Echocardiography Core Lab within 
10 days of completion. Each site will be responsible for identifying experienced 
sonographers (echocardiographic technicians) who will perform study echocardiograms, which will be a limited version of the standard echocardiographic examination. Sites will be supplied with training materials that will describe in detail the methodology for obtaining study echocardiograms. Training sessions will be conducted and documented for all participating sites.  
 A subset of a standard echocardiographic examination will be performed. All subjects will undergo 2- D echocardiography with the following views:  
 
Parasternal Long Axis View (PLAX):  
o 2D imaging of Left Ventricle to determine septal and posterior wall thickness and LV 
diameters at end diastole  and end systole. Make measurements in the mid -LV 
adjacent to postero -lateral papi[INVESTIGATOR_286689]. LV outflow diameter is measured in the 
frame following aortic valve opening. 
o Color Doppler imaging performed for presence of mitral regurgitation. Color Doppler 
imaging should be performed with a nyquist limit (scale) .5 -.6m/sec. Demonstrate 
MR jet at the coaptation of the mitral leaflets for measurement of jet wid th. 
 
Parasternal Short Axis View (PSAX)/right ventricular outflow view: 
o Pulsed Wave Doppler  of the right ventricular outflow tract velocities should be 
obtained just proximal to the pulmonary valve leaflets to measure pre -ejection period 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 64 of 67  
  (PEP) – PEP is the  time from onset of the QRS complex to the onset of RV outflow 
systolic velocity envelope. Velocities must be recorded at a 100mm/s sweep speed.  
 
 
 
Api[INVESTIGATOR_2855] 4 -chamber view:  
o 2D imaging to demonstrate the RA, RV, LV and LA chambers within the sector 
image at t he proper depth in at least 3- [ADDRESS_418684] ed to clearly display systolic jet envelope profile at 
a 100mm/s sweep speed.  
o Pulsed -wave Doppler  of mitral inflow velocities should be obtained at the mitral 
leaflet tips, recorded at 100mm/s sweep speed. Measurements will include E -wave 
and A -wave velocities, E -wave deceleration time and diastolic filling time.  
o Pulsed -wave tissue Doppler imaging (TD I) is performed at the lateral and septal LV 
base (i.e., mitral annulus) to obtain systolic (S’) and diastolic myocardial velocities (E’). The sample volume size should be set at a 3 -5mm axial length; Doppler signal 
gain and velocity scale should be adjust ed to display peak S’ and Em velocities, 
recorded at 100mm/s sweep speed. Measurements include time from onset of QRS to peak (or onset) of S’ velocity at each site.  
 
Api[INVESTIGATOR_2855] 2 -chamber view:  
o 2D imaging of LV and LA endocardial borders demonstrated in the sector image at 
the proper depth setting in at least 3 -5 cardiac cycles.  
o Color Doppler imaging performed for the presence of mitral regurgitation.  
 
Api[INVESTIGATOR_2855] 5 -chamber view:  
o Pulsed -wave Doppler  sample volu me of the LV outflow tract.  Display closing 
“click” of the aortic valve with well -defined systolic velocity envelope recorded at 
100mm/s sweep speed. Measurements include pre- ejection period (PEP) and velocity -
time integral (VTI).  
 
o Continuous -wave Doppler  used to obtain peak aortic flow velocity, with well -defined 
spectral envelope that includes aortic valve opening and closing clicks, recorded at 100mm/s sweep speed.  
 
27.2. Six-Minute Walk Test  
The six -minute  walk  test is a self -paced sub -maximal exercise test that has proven useful as 
an outcome measure for patients with congestive HF. Previous studies18,[ADDRESS_418685] shown that 
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418686] is well tolerated by [CONTACT_338661]’s daily 
activities than maximal exercise testing.  
 
The walking test should be conducted in an enclosed corridor on a course approximately 100 
feet (30.5 meters) long. The length should be marked in either feet or meters to allow easy 
measurement of the distance walked. The corridor should not be heavily trans ited and should 
be free of obstacles and distractions. Chairs should be placed at either end of the course so 
that subject s may rest when needed. If for any reason an individual physician does not 
recommend a subject  to perform the six -minute  walk then rec ord the reason on the case 
report form.  
 
Instructions 
The subject  is to take nothing by [CONTACT_338662]. Prescribed medications should be taken as usual. Subject s should be advised not to 
smoke for at least two hours prior to exercise and to wear suitable footwear. Subject s are 
instructed to walk the marked course from end to end at their own pace, covering as much 
distance as possible in six -minute s. Subject s may slow down or stop to rest if necessary, but  
should be instructed to resume walking when they feel they are able to do so. The aim is that at the end of the test, the subject  believes that they could not have walked any further in the 
six-minute s. 
 The following instructions are to be read to the subject  verbatim:  
 “The purpose of this test is to determine how far you can walk in six -minute s. You will start 
here and go to the end of the hall, turn around, and walk back. After arriving back at the starting  point, you will go back and forth again. Go back and forth as  many times as you can 
in the six -minute  period. If necessary, stop and rest and stay here until you can start again. 
However, the  most important thing about the test is that you cover as much distance as 
possible during the six -minute  period.”  
  “I will let you know when each minute has passed. When I say ‘STOP’ after six-minute s, 
please stand right where you are.’  
 
“Do you have any questions about the test?”  
 
“Please explain to me what you are going to do.”  
 “Are you r eady?”  
 
“Start when I say ‘GO’.”  
 
Protocol  
 
The walk test should be performed after completing the physical assessment of the subject . 
Subject  safety is the highest priority, and the walk test should not be initiated if the physician,  
coordinator or subjec t has concerns regarding the subject ’s ability to perform the test. If the  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page [ADDRESS_418687]  at the beginning of the course. 
2. Simultaneously say ‘GO” and start the watch. Observe the subject  for the six-minute  
period while recording the successful completion of each length of the course. In order  to 
standardize the test, encouragement is not of fered during the walk. Do not  otherwise 
speak to the subject  except to answer questions he or she poses. Stop the test if  the subject  
reports severe shortness of breath, muscular pain, dizziness, or angina symptoms.  
3. At the end of the six -minute  interval , tell the subject  to “STOP”.  
4. Record the distance traveled to the nearest foot or meter. If the subject  ceases participation 
prior to the end of the six -minute  interval, record the distance covered (to the  nearest foot or 
meter) and the subject ’s heart rate at the time he or she stops walking.  
 
27.3. Kansas City Cardiomyopathy Questionnaire (KCCQ)  
The KCCQ is a disease- specific instrument for monitoring the health status and quality of life 
of subjects with congestive heart failure.  It includes a total of 23 items that assess quality of 
life in the following domains: physical function, symptom frequency and severity, symptom stability, self -efficacy and knowledge, social function, and overall quality of life.  These 
domains can be combined into a functional st atus summary score (derived from the physical 
function and symptom scales) and an overall summary score which combines the physical function, symptom, social function and quality of life domains.  The KCCQ has been 
validated in subjects with CHF using a va riety of standard techniques (1), is highly 
reproducible among stable subjects. In cross -sectional analyses, the KCCQ has been shown 
to be highly correlated with event -free survival. Finally, the responsiveness of the KCCQ as 
assessed by [CONTACT_941] “responsiveness statistic” (ratio of mean change among subjects with 
improved CHF to the standard deviation among stable subjects) is superior to other measures 
including the SF -36, the Minnesota Living with Heart Failure Questionnaire, and NYHA 
classification (Spertus JA, personal communication).   
  
References  
1.  Green CP, Porter CB, Bresnahan DR, Spertus JA.  Development and evaluation of the 
Kansas City Cardiomyopathy Questionnaire:  a new health status measure for heart failure.  J Am Coll Cardiol 2000;35:1245- 55. 
 
27.4. SmartDelay Step -by-Step Guidance  
Follow these steps to perform SmartDelay tes t. 
Step 1. Navigate to the SmartDelay Optimization screen  
• From the programmer (PRM) main screen, choose the Settings tab  
• From the Settings tab, choose Settings – Normal Brady/CRT ,  
C2067               Form/Template  90702637 Rev/Ver AH 
Confidential                                          S MART  CRT Study Protocol, 92055794, Rev/Ver  D 
                                                                                                                       Page 67 of 67  
  • From the Settings – Normal Brady/CRT  screen, choose SmartDelay Optimization  
• The nominal Temporary Paced LRL  is set at [ADDRESS_418688]’s intrinsic heart rate.  
• Program LV Offset to 0ms.  
Step 2. Run the SmartDelay test  
• From the SmartDelay Optimization screen, choose Start Test. The test typic ally last 
up to 2.5 minutes.  
• SmartDelay will recommend AV delay  and Pacing Chamber  (BiV or LV Only ).  
• If the SmartDelay test fails, the nominal value will be displayed.  
Step 3. Program AV Delays and Pacing Chambers  
• If following the recommended AV Delay  and Pacing Chamber  value determined by 
[CONTACT_338663], choose Copy Suggested Settings  and push the program button to 
program the device.  
Step 4. Record the required value  
• Record in the follow -up eCRF both the SmartDel ay recommendation and final 
programmed value for AV Delay  and Pacing Chamber . Also record the final 
programmed LV offset . 
• Once the Pacing Chamber  is selected for a subject at Randomization  Visit, the same 
Pacing Chamber  must be used throughout the trial for that subject.  
 
 